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1Welcome
Welcome to the Diamantina Health Partners Forum “Meeting 
of Minds: translate – transfer – transform”.
Diamantina Health Partners is Queensland’s first Academic 
Health Science Centre. It aims to integrate research, training 
and education, and clinical care to deliver innovative 
evidence-based healthcare to the population.
It is fitting that the focus of our second annual Forum is on 
integration in the health sector—the translation of research, 
the transfer of knowledge, and the transformation of health 
care delivery. 
Over the coming days, sessions will include presentations 
on translating research in chronic disease, ageing and 
cancer. Others will look at the transfer and dissemination 
of knowledge into the clinical setting and the community, 
and how innovation is being used to transform health care 
delivery.
The mould for Diamantina Health Partners was set by highly 
successful international Academic Health Science Centres 
such as the Mayo Clinic in the United States of America. 
This year, we are honoured and delighted to have Dr Victor 
Montori of the Knowledge and Evaluation Research Unit at 
the Mayo Clinic as one of our international keynote speakers. 
Dr Montori serves as Director of the Health Care Delivery 
Research Program in the Mayo Clinic Centre for the Science of 
Health Care Delivery.
We will also be joined by Dr David S Alberts, Regents 
Professor of Medicine, Pharmacology, Nutritional Science, 
and Public Health at the University of Arizona College of 
Medicine, and Director Emeritus of the Arizona Cancer Centre.
A new addition to this year’s event is a pre-forum symposium 
showcasing the potential human benefits of translational 
research. Entitled Research and Innovation Ideas, the 
symposium features five-minute presentations from 
Diamantina Health Partner researchers describing the project 
benefits of their research. As we recognise the essential role 
health and medical research plays in the delivery of improved 
patient outcomes, Diamantina Health Partners is offering 
$10,000 in funding to the winning presentation.
The Forum is again an opportunity to advance collaborations. 
As with our successful inaugural event in 2013, we are 
bringing together researchers, educators, clinicians and 
industry partners to pursue excellence through integration of 
the full spectrum of endeavours to deliver health benefits to 
our patients and population.
We would like to extend our appreciation to all of our 
sponsors and supporters, particularly Pathology Queensland 
(SERTF fund) for their support and funding contribution 
towards the Forum.
We take this opportunity to thank you for joining us and 
we trust that you will find the meeting of minds at our 2014 
Forum to be one of the greatest of the year.
Dr David Theile AO Areti Gavrilidis 
Chairman Executive Consultant 
Diamantina Health Partners Diamantina Health Partners
2Meeting of Minds
Forum 2014
Contents
Welcome
Speaker  
Synopses
General 
Information
Pre-Forum  
Symposium: 
“Research and 
Innovation  
Ideas”
Organising 
Committee
Author Index
Program
Research  
and Innovation 
Ideas 
ABSTRACTS
International 
Keynote  
Speakers
Turn Your  
Ideas Into  
Action!
Chairs and 
Presenters
21
26
27
28
50
1
3
4
5
8
10
3General Information
Venue
Translational Research Institute (TRI)  
37 Kent Street 
Woolloongabba QLD 4102 
(within Princess Alexandra Hospital Campus)
Reception and taxi drop-off: Diamantina Rd West 
(enter via O’Keefe St), Woolloongabba
Name tags 
We ask you wear the name tags provided for the days you 
attend the forum. 
These tags need to be worn to ensure you have access to the 
catering area of the forum.  
Catering 
A water station is located within the foyer of the auditorium 
for your use. Catering stations for morning tea, lunch and 
afternoon tea are located in the atrium of the TRI building. 
Please ensure you wear your name tag for each catering 
session otherwise you will be denied access to the catering 
areas. Special dietary meals have also been catered for and 
will be found on the special dietary table.
Networking Forum 
Wednesday,30 April 2014 
5.15pm - 7.15pm
Translational Research Institute Atrium 
We encourage you to stay for the networking forum, at the 
conclusion of the Pre-Forum Symposium. 
The forum will be attended by Hon Lawrence Springborg MP, 
Minister for Health.
Registration desk and times 
Please see the event staff at the registration desk which is 
located within the Auditorium foyer. 
Feedback 
At the conclusion of the forum all attendees will be emailed 
a link to survey your thoughts about the forum including 
catering, branding and topics.  
We ask you spend 2 minutes completing this survey. In 
addition, we ask you provide feedback through the forum 
twitter page @DiamantinaHP  #DHPforum  
Presentations 
You will be sent a link within 2 weeks where all approved 
presentations provided by speakers will be provided. 
Presentation of the Research 
and Innovation Award 
Finalists will present their 5 minute presentation on 
Wednesday, 30 April from 1.30pm. 
The winner/s of the research and innovation award will be 
presented on Friday, 2 May at the closing ceremony. We 
encourage all finalists to join us in the auditorium for this 
presentation ceremony. 
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David Theile Diamantina Health Partners  
Areti Gavrilidis Diamantina Health Partners  
Selena Bartlett Queensland University of Technology  
Helen Benham The University of Queensland  
Michelle Bordignon I Am Events  
Caroline Davy The University of Queensland Diamantina Institute to December 2013
Kate Gadenne University of Queensland Faculty of Medicine and Biomedical Sciences from January 2014
Penny Geraghty Princess Alexandra Hospital  
Anita Gibson Diamantina Health Partners  
Phoebe Grealy Mater Research from February 2014
Sally Grosvenor Queensland University of Technology  
Rachael Hazell Translational Research Institute to January 2014
Cas Hunter Mater Health Services to December 2013
Jennifer Martin The University of Queensland School of Medicine  
Kirsten O'Leary The University of Queensland Faculty of Health and Behavioural Sciences from January 2014
Lauren Townrow Translational Research Institute from January 2014
Maria Wojciechowski Princess Alexandra Hospital  
Bruce Wyse The University of Queensland Diamantina Institute  
Organising Committee
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WEDNESDAY 30 APRIL 2014           
PRE-FORUM SYMPOSIUM “RESEARCH AND INNOVATION IDEAS”
TIME SUBJECT SPEAKER
1:00pm REGISTRATION
1:30pm – 3.15pm A spectrum of translational research prospects 
proudly supported by PA Research Foundation
Chair: Professor Frank Gannon
3:15pm – 3:30pm Afternoon Tea
3:30pm – 5:15pm A spectrum of translational research prospects 
proudly supported by PA Research Foundation
Chair: Professor Ken Ho
5:15pm Networking event
6Meeting of Minds
Forum 2014
THURSDAY 1 MAY 2014           
CHRONIC DISEASE AND AgEINg
TIME SUBJECT SPEAKER
7:45am – 8:30am REGISTRATION
8:30am – 8:45am Opening 
Hon Ian Walker, Minister for Science, Information Technology, 
Innovation and the Arts
Hon Ian Walker MP
8:45am – 9:30 am Keynote Address 
proudly supported by Pathology Queensland (SERTF)
Chair: Dr David Theile 
Minimally Disruptive Medicine: innovating a respectful approach 
to chronic care delivery
Professor Victor M. Montori, Mayo Clinic
9:30am – 10:40am Translation: The challenges and rewards of science to clinical 
capability
Chair: Professor Zee Upton
Translating science into practice in systems development:  case 
studies in geriatrics
Professor Len gray
From science to commercialisation and clinical capability in 
rheumatoid arthritis
Professor Ranjeny Thomas
Translating a diabetes therapy from mice to man Professor Michael Mcguckin
10:40am – 11:00am Morning Tea
proudly supported by QFAB*
11:00am – 12:30pm Transfer: Knowledge dissemination into practice Chair: Professor Bruce Abernethy
Bridging the knowledge-practice gap through education and 
collaboration
Professor David Johnson 
The measurement of frailty in older inpatients to improve clinical 
care
Dr Ruth Hubbard
Why exercise works – is modulation of redox control involved? Professor Jeff Coombes
Controlling your RAgE – new insights into the pathogenesis of 
type 1 diabetes
Professor Josephine Forbes
Obesity – it’s everyone’s challenge Associate Professor Jon Whitehead
12:30pm – 1:30pm Lunch
1:30pm – 3:00pm Transform: Change practice Chair: Professor John Prins
Streamlining the diagnosis of specifically treatable forms of 
hypertension
Professor Michael Stowasser
From “this is the way we do things” to “how should we do things” Professor Jennifer Martin
Change practice at a state-wide-level: learnings from the clinical 
networks
Associate Professor Paul Varghese
Closing the gap for treatment of liver disease Professor Elizabeth Powell
global Longitudinal Strain as a novel predictor of outcome Associate Professor Tony Stanton 
3:00pm – 3:30pm Afternoon Tea
3:30pm – 5:15pm Transform: System development – Safety Efficacy Economics Chair: Dr Richard Ashby
Pursuit of evidence:  what can be done? Associate Professor Carmel Hawley 
Evidence, ethics and budgets – can they be reconciled? Associate Professor Ian Scott
Scarcity, decision making and health services research Professor Nick graves
Research ‘value’: the health service perspective Dr John Wakefield
Placing patients at the center of our research and our practice Professor Victor M. Montori
Program
* QFAB provides bioinformatics and biostatistics services for life science researchers and clinicians.
7FRIDAY 2 MAY 2014 
COMPREHENSIVE CANCER CENTRE 
TIME SUBJECT SPEAKER
7:15am – 8:30am Breakfast session (by invitation)
Evidence and innovation in clinical practice
proudly supported by Pathology Queensland (SERTF) 
Facilitator 
Professor Ross Young
7:45am – 8:30am REGISTRATION
8:45am – 9:30am Building a comprehensive Cancer Center in the 21st Century
proudly supported by Pathology Queensland (SERTF)
Chair: Dr David Theile 
Regents Professor David S. Alberts 
University of Arizona Cancer Centre 
via pre-recorded message 
9.30am – 10:40am Translation stories: Science to care Chair: Associate Professor Paula Marlton
Science preventing cancer – achievements and prospects Professor Ian Frazer
Developing targeted therapies to treatment resistance in 
advanced prostate cancer 
Professor Colleen Nelson
Personalised medicine in oncology Professor Ken O’Byrne
Vascular bone marrow niches protect Acute Myeloid Leukaemia 
Stem Cells from chemotherapy
Associate Professor Ingrid Winkler 
10:40am – 11:00am Morning Tea
proudly supported by illumina*
11:00am – 12:45pm Transfer knowledge into practice Chair: Professor Joanne Atkins
Stories of research adjusting clinical care – history of change 
within clinical research
Associate Professor Damien Thomson
Modifying tumour hypoxia in the clinic to improve outcomes in 
head and neck cancer
Associate Professor Sandro Porceddu
Targeting inflammation in epithelial ovarian cancer Dr Jim Coward
Changes over time in head and neck cancer: perspectives of a 
surgeon
Associate Professor Ben Panizza
Implementing practice change in chronic pain management Professor Janet Hardy
12:45pm – 1:30pm Lunch
1:30pm – 3:00pm Transform delivery of healthcare Chair: Professor Ian Frazer
Mobile technology in healthcare: apropos consumer mobile 
teledermatology
Professor Peter Soyer
Melanoma, 2014- Targeting Cancer Pathways Dr Victoria Atkinson
Monitoring Barrett’s Oesophagus Associate Professor Andrew Barbour
Ductal Carcinoma in situ(DCIS) of the breast – A case for change 
in strategy
Associate Professor Euan Walpole
Towards personalised medicine Associate Professor Devinder gill
3:00pm – 3:30pm Afternoon Tea
proudly supported by illumina*
3.30pm – 5:00pm Panel session Chair: Associate Professor Euan Walpole
Taking evidence and innovation into the cancer clinic Dr Warren Joubert
Professor Jennifer Martin
Associate Professor Paula Marlton
Associate Professor Nick Saunders
Professor Peter Soyer
5.00pm                        Research Award, Close and Vote of thanks Dr David Theile
2015  Announcement                                                Areti Gavrilidis
* illumina is a leading developer, manufacturer, and marketer of life science tools and integrated 
systems for the analysis of genetic variation and function. 
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International Keynote Speakers
Victor M. Montori
MD MSc
Director, Healthcare Delivery Research Program and Knowledge  
and Encounter Research Unit, Mayo Clinic
Dr Montori is a professor of medicine at Mayo Clinic 
Rochester. He serves as a physician consultant in the Division 
of Endocrinology, Diabetes, Metabolism and Nutrition, and 
as director of the Healthcare Delivery Research Program.  
He has joint appointments in the Division of Healthcare 
Policy and Research at Mayo and the Department of Clinical 
Epidemiology and Biostatistics at McMaster University in 
Canada.
Dr Montori is an internationally-recognised researcher 
focusing on understanding and improving the process by 
which clinicians and patients use knowledge to make better 
decisions and improve patient outcomes. He is currently the 
lead investigator of the Knowledge and Encounter Research 
(KER) Unit, and previously was the co-director of the NIH-
funded Translating Comparative Effectiveness Research 
(TRACER) Unit of the Mayo Center for Translational Science 
Activities. He has authored over 300 research reports 
published in top medical journals.
Dr Montori received the Excellence in Teaching Award at Mayo 
Medical School for his work as both a teacher and a mentor. 
He serves on the editorial boards of prestigious medical 
journals, including Annals of Internal Medicine, has delivered 
keynote presentations at major academic institutions 
worldwide, and has chaired a special panel of the National 
Institutes of Health focused on translating diabetes research 
into practice.  He is a member of the expert panel of the AHRQ 
Innovations Exchange.
Dr Montori received his MD degree from the Universidad 
Peruana Cayetano Heredia in Peru. He completed his 
residency training and became chief resident in the 
Department of Internal Medicine at Mayo Clinic. He earned 
his MSc degree in biomedical research at Mayo graduate 
School and completed a fellowship in endocrinology at 
Mayo. Dr Montori also completed a research fellowship in the 
Department of Clinical Epidemiology at McMaster University 
in Canada.
9David S. Alberts
MD
Regents Professor of Medicine, Pharmacology, Nutritional Sciences and Public 
Health, and Director Emeritus of the University of Arizona Cancer Center
Dr Alberts is a Regents Professor of Medicine, Pharmacology, 
Nutritional Sciences and Public Health, and is the Director 
Emeritus of the University of Arizona Cancer Center (UACC). 
Under Dr Alberts’ leadership the extensive research portfolio 
of the UACC includes more than $50 million in annual 
research funding, including four large NCI interdisciplinary 
programs.  
Dr Alberts is the recipient of the Distinguished Senior 
Investigator Salmon Award. In 2003 and 2004, Dr Alberts was 
honored by the American Association for Cancer Research 
with its Joseph Burchenal Clinical Research Award and its 
3rd Annual Excellence in Cancer Prevention Research Award, 
respectively.
Clinically, Dr Alberts has pioneered new treatments for 
advanced ovarian cancers, including in vitro tumor cell 
chemosensitivity testing for personalised medicine strategies. 
Presently, Dr Alberts helps to coordinate Phase I and II 
and pharmacokinetic drug studies for molecularly-targeted 
chemopreventive agents. His research is concentrated on the 
evaluation of new surrogate endpoint biomarkers for cancer 
prevention trials with a special focus on precursor lesions 
for bladder, breast, colon, cervical, endometrial, ovarian, 
prostate, and skin cancers, using quantitative histopathology 
approaches. 
His NCI-funded drug and diagnostics research has resulted 
in more than two dozen patents and the co-founding of four 
Arizona pharmaceutical and biotechnology companies.  Dr 
Alberts has authored or co-authored more than 550 peer 
reviewed publications and served as Co-Editor-In-Chief of 
Cancer Epidemiology, Biomarkers and Prevention from 2003-
2008.  
Currently, he serves as a Principal Investigator for the NCI-
funded Chemoprevention of Skin Cancer Program Project 
(1980-2016), the Native American Cancer Prevention U54 
Partnership (2001-2014), the R25T Cancer Prevention and 
Control Post-doctoral Training grant (2001-2015) and the 
Phase I/II Chemoprevention Consortium Contract (2003-
2017).  
Dr Alberts earned his MD from the University of Virginia. He 
conducted his internship at the University of Wisconsin, 
before becoming a Clinical Associate in medical oncology at 
the National Cancer Institute’s Baltimore Cancer Research 
Center. Dr Alberts conducted his internal medicine residency 
at the University of Minnesota, and obtained Board 
certification in Medicine and Medical Oncology in 1973. He 
joined the University of Arizona College of Medicine in 1975 
as an Assistant Professor, where he has served for nearly 38 
years.
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Chairs and Presenters
Dr Victoria Atkinson 
MBBS FRACP
Dr Victoria Atkinson is a Senior Medical Oncologist who has 
worked at the Princess Alexandra Hospital since 2007 and 
greenslopes Private Hospital since 2011.  Her undergraduate 
training was undertaken at the University of Queensland and 
she completed her FRACP in Medical Oncology in 2006.  Her 
tumour interests include Melanoma and gastro-intestinal 
tumours. She has extensive experience with targeted 
therapies for melanoma including Vemurafenib, Dabrafenib, 
Trametinib, Ipilimumab and Nivolumab.
Associate Professor  
Andrew Barbour
MBBS (Hons) PhD FRACS FACS
DHP Upper GI Cancer Stream Leader  
within the Comprehensive Cancer Centre
Associate Professor Andrew Barbour is a Surgical Oncologist 
at the Princess Alexandra Hospital (PAH).  He is a translational 
researcher at The University of Queensland School of 
Medicine, PAH where his research has focused on using 
genomic, mRNA expression and next generation sequencing 
data to classify oesophageal adenocarcinoma (OAC) and 
identify biomarkers of outcome of OAC and melanoma. In 
addition, he was a James IV Travelling Fellow in 2013.  He 
is the Principal Investigator for multicentre phase II trials in 
oesophageal and pancreatic cancer, funded by the NHMRC.
Professor Bruce Abernethy
BHMS (Hons) PhD
DHP Board Member
Professor Abernethy is a first class Honours graduate and 
university medallist from The University of Queensland (UQ), 
a PhD graduate from the University of Otago, an International 
Fellow of the American Academy of Kinesiology and Physical 
Education, a Fellow of the Australian Sports Medicine 
Federation and a Fellow of Exercise and Sport Science 
Australia. 
Professor Abernethy is Executive Dean of the UQ Faculty of 
Health and Behavioural Sciences.  He was Deputy Executive 
Dean and Associate Dean (Research) for the former Faculty of 
Health Sciences (from 2011-2013) and from 2004 to mid-2011 
was the Director and inaugural Chair Professor of the Institute 
of Human Performance at the University of Hong Kong.
His research interest is in the control and acquisition of 
skilled movement, with a particular focus upon understanding 
the processes underpinning the expert perception and 
production of patterns of human movement.  
Dr Richard Ashby
AM MBBS BHA FRACgP FRACMA FACEM FIFEM
DHP Board Member
Dr Ashby is a member of the Board of the Translational 
Research Institute, and is a Director of the Australian e-Health 
Research Centre and the Australian Prostate Cancer Research 
Centre.  Dr Ashby is the Chief Executive of Metro South Health 
and one of the state’s most experienced clinicians and 
clinical administrators. 
He was most recently the Executive Director and Director of 
Medical Services at the Princess Alexandra Hospital (PAH).  He 
was appointed Director of Emergency Medicine and  Executive 
Director Medical Services at the Royal Brisbane and Women’s 
Hospital (RBWH) and has also acted as District Manager at 
both the RBWH and PAH until transferring to his position at 
the PAH in June 2006.
In 2010, Dr Ashby was awarded a Member of the general 
Division of the Order of Australia for service to emergency 
medicine, to medical administration, and to a range of 
professional associations. He is active across a broad 
range of medical areas including teaching, research and 
consultancy.
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Professor Jeff Coombes
BEd (Hons), B AppSc MEd PhD
Jeff is a Professor in the School of Human Movement Studies 
at UQ. His research interests focus on determining the optimal 
exercise prescription for improving health. With theoretical 
backgrounds in biochemistry and physiology he conducts 
human studies and basic science projects.  His findings have 
emphasised the importance of cardiorespiratory fitness for 
health benefits and many of his current projects are using 
high intensity interval to improve fitness and investigate 
outcomes.  The basic science projects are identifying the 
mechanisms that explain the health benefits of exercise 
and include work in the cardiovascular and musculoskeletal 
systems at cellular and molecular levels.   He is also a 
passionate advocate on the importance of fitness for health 
and delivers many presentations to impact on public health.  
His research group comprises doctors, postdoctoral fellows 
and PhD students and uses the extensive resources of the 
exercise physiology and exercise biochemistry laboratories in 
the School of Human Movement Studies.
Dr Jim Coward 
MBBS BSc (Hons) MRCP PhD FRACP 
DHP Gynaecological Cancer Stream Leader  
within the Comprehensive Cancer Centre
Dr Jim Coward is a medical oncology specialist in 
gynaecological malignancies at the Mater Adult Hospital and 
senior research fellow in the Cancer Therapeutics group at the 
Mater Research Institute.  He undertook specialist training at 
the Royal Marsden Hospital, London and was awarded a PhD 
from the Barts Cancer Institute, London in 2010.  The remit 
of his research revolves around efficient translation of novel 
bench-side discoveries in cancer-related inflammation into 
combinatorial clinical trials.
Professor Jeff Dunn
PhD
Professor Jeff Dunn is the Chief Executive Officer of Cancer 
Council Queensland. He currently holds Professorial 
appointments with the Griffith University School of Public 
Health where he is also a member of the Behavioural Basis 
for Health Program and University of Queensland’s Faculty of 
Social and Behavioural Science.  He has a central focus on 
the development and delivery of supportive care for cancer 
patients and is actively involved in research in this field.  
This focus includes supportive care strategies that underpin 
cancer prevention and improve community awareness of the 
disease.
He continues to serve on numerous advisory and planning 
committees to Cancer Australia and the Union for 
International Cancer Control (UICC) and is on the Board of the 
International Psycho-oncology Society (IPOS). He is a Director 
and Secretary of the International Psycho-Oncology Society 
(IPOS) and an editorial Board member for Psycho-Oncology 
Journal. He is also an Executive committee member and 
President Elect of the Asia Pacific Organisation for Cancer 
Prevention (APOCP).
Professor Josephine Forbes
PhD
Professor Josephine Forbes completed her PhD in Nephrology 
in 1999 at the Royal Children’s Hospital. She is currently an 
NHMRC Senior Research Fellow and has held research grants 
from the NHMRC of Australia, the Juvenile Diabetes Research 
Foundation and the National Institutes of Health (USA).
Prof Forbes’ work to date has resulted in more than 100 
publications with more than 4500 citations. She has received 
awards including the Commonwealth Health Minister’s 
Award for Excellence in medical research in 2010, an NHMRC 
Achievement Award in 2009, a Young Tall Poppy Award in 
2008 and a Young Investigator Award from the International 
Diabetes Federation.  She heads the glycation and Diabetes 
team at the Mater Research Institute UQ where they focus on 
how advanced glycation contributes to the pathogenesis of 
diabetes and its complications such as renal disease.
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Professor Ian Frazer 
BSc MBBS PhD FRS FAA
DHP Board Member
Professor Ian Frazer who is internationally renowned for 
the co-creation of the technology for the cervical cancer 
vaccine began his career as a renal physician and clinical 
immunologist in Edinburgh, Scotland.  He emigrated to 
Melbourne in 1981 to work at the Walter and Eliza Hall 
Institute of Medical Research.  In 1985, he accepted a 
teaching post with The University of Queensland and 
was appointed Director of The University of Queensland 
Diamantina Institute in 1991.  In early 2011, he relinquished 
directorship of the Institute to take on the position of CEO and 
Research Director of the Translational Research Institute.  
He retains an active research program at the Institute in 
immune responses to cancer. In 1991, along with colleague, 
Dr Jian Zhou, he developed the virus-like particle technology 
which has become the basis of vaccines to prevent cervical 
cancer.
Professor Frazer is the recipient of many awards including 
the 2005 CSIRO Eureka Prize for Leadership in Science; 
Queenslander of the Year, and Australian of the Year in 
2006; Prime Minister’s Prize for Science and Balzan Prize for 
Preventative Medicine in 2008; Honda Prize in 2009.  In 2011 
he was elected as a Fellow of the esteemed Royal Society of 
London.
Professor Frank Gannon
BSc PhD
Professor Frank gannon is the Director and CEO of the 
QIMR Berghofer Medical Research Institute. He joined QIMR 
Berghofer in January 2011, having been Director general and 
board member of Science Foundation Ireland since 2007. 
He obtained his PhD from the University of Leicester, England 
in 1973 and worked subsequently in the USA, France, 
Ireland and germany where he was Executive Director of the 
European Molecular Biology Organisation from 1994-2007.
Associate Professor  
Devinder Gill 
MB ChB MRCP FRCPath (Lond)
Dr gill is the Director of Haematology and the founding Chair 
of Cancer Collaborative group at Princess Alexandra Hospital 
(PAH).  He chaired the Aggressive and Hodgkin’s Lymphoma 
for the Australasian Leukaemia and Lymphoma group (ALLg) 
and until recently was a member of the ALLg Board. He 
was a founding member of the ALLG Laboratory Scientific 
Committee and member of the ALLg Tissue Bank Management 
Committee. He is founding Co-Chair of the International 
Meeting “New Direction in Leukaemia Research Meeting” and 
founding member and current Vice-President of the Chronic 
Lymphocytic Leukaemia Australian Research Consortium.
He has actively promoted disseminated research having 
developed the haematology clinical trials unit and research 
infrastructure at PAH including molecular biology laboratory, 
and DNA micro arrays facilities. He pioneered the cessation of 
immunosuppression during chemotherapy resulting in much 
improved outcome in PTLD patients.  He was the founding 
member of the MInT Study Steering group, a Phase III study 
to show the superiority of Rituximab (Mabthera) when added 
to conventional CHOP therapy in patients age <60 years with 
aggressive lymphoma. The addition of Rituximab was the 
first major advance in 30 years in the treatment of large cell 
lymphoma and is now established as the standard of care.
Professor Nick Graves
BA (Hons) MA PhD 
Professor Nicholas graves is developing Health Services 
Research in Queensland with nationally competitive grants 
and by engaging with health services professionals.  He works 
jointly between the Queensland University of Technology and 
Queensland Health.  His applied research brings economics 
to the study of healthcare acquired infection, screening 
for chronic and infectious diseases and interventions that 
change health related behaviours.  He is motivated by 
research that improves health services.  He is also interested 
in quantifying the role of randomness and cost in allocating 
research funding.  He manages a research team and 
supervises PhD students.
Chairs and Presenters
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Professor Len Gray 
MBBS MMed PhD FRACP FACHSE FAAg FANZSgM
Professor Len gray is Director of the Centre for Research 
in geriatric Medicine and the Centre for Online Health at 
The University of Queensland.  He has formal training as 
a specialist geriatrician and in health administration.  He 
assumed the role of Professor in geriatric Medicine at The 
University of Queensland in 2002.  He established the Centre 
for Research in geriatric Medicine in 2009, and took up the 
additional role of Director of the Centre for Online Health in 
2010. 
Previously he held senior management positions in the public 
health system in Victoria, in general management and aged 
care services.  His research interests focus on aged care 
policy, models of aged care service delivery, assessment 
and care planning systems, and in recent years, e-health and 
telemedicine strategies.  He leads international development 
of the inter RAI Acute Care system of assessment, and is the 
Australian coordinator for interRAI.
Professor Janet Hardy
BSc MBChB MD
Professor Janet Hardy trained in medical oncology at Auckland 
Hospital.  She was appointed Head of the Department of 
Palliative Medicine at the Royal Marsden Hospital in London 
in 1991.  In 2003, she returned to Australia and is now the 
Director of Palliative Medicine for the Mater Health Services 
and is the Clinical Research Program Leader for the Centre 
for Palliative Care Research and Education in Brisbane.  She 
heads the “Improving Treatment of Disease” theme, one of 
the four themes developed to support research through the 
Mater Medical Research Institute.
Her major research interests are in the clinical development of 
new analgesics and analgesic formulations, the management 
of cancer–related nausea and vomiting, and in facilitating 
research in palliative care.  Her mission is to improve the 
evidence-base on which the practice of palliative care is 
founded.
Associate Professor  
Carmel Hawley
MBBS (Hons) M Med Sci FRACP
Dr Carmel Hawley is a consultant nephrologist at the Princess 
Alexandra Hospital and Associate Professor at The University 
of Queensland School of Medicine.  She is the inaugural and 
current chair of the Operations Secretariat of Australasian 
Kidney Trials network (AKTN) formed in 2005. The Network has 
published its first completed Randomised Controlled Trial, 
the HONEYPOT trial (a trial in the peritoneal dialysis cohort) 
and has a number of other trials underway in Haemodialysis 
and Chronic Kidney Disease. The network has been successful 
in engaging the nephrology community in Australia and New 
Zealand, and in addition, is active in forming collaborations 
with leading researchers from other countries. 
In the last 5 years Dr Hawley has published over 100 scientific 
papers and has been awarded numerous grants particularly 
for the conduct and operational aspects of AKTN trials.  She 
has a particular interest in the integration of research into 
standard clinical practice, funding mechanisms for clinical 
research, and innovative trials methods. 
Professor Ken Ho 
MBBS FRACP FRCP (UK) MD
DHP Board Member
Professor Ken Ho took up the position of Chair, Centres of 
Health Research, Princess Alexandra Hospital, Professor of 
Medicine, University of Queensland and Adjunct Professor, 
Queensland University of Technology in 2011.  He was 
previously Chairman, Department of Endocrinology, St. 
Vincent’s Hospital, Professor of Medicine, University of New 
South Wales, and Head, Pituitary Research Unit, garvan 
Institute of Medical Research in Sydney. 
His research focuses on hormones and metabolism, 
investigating the causation of and treatments for obesity, 
muscle loss and physical frailty.  The work is strongly 
translational; closely integrating laboratory and clinical 
studies, directed at understanding how hormones act on cells 
and on the whole body.
He received the inaugural Senior Plenary Award of the 
Endocrine Society of Australia (2011), the Visiting Trust 
Professor (2000) and the Asia Oceania Medal of the British 
Endocrine Society (2008).
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Dr Ruth Hubbard
BSc MBBS MRCP MSc MD
Dr Ruth E. Hubbard recently moved to Brisbane, Australia 
from her native Wales, having been appointed to a joint 
position as Senior Lecturer in geriatric Medicine at the 
University of Queensland and Consultant Physician in 
geriatric Medicine. As a clinical academic, she has always 
combined hospital practice with research and teaching. She 
completed an MSc in Medical Education in 2005 and an 
MD on pathophysiological changes in frail older people in 
2008. She was then awarded a grant from the Peel Research 
Trust, London to pursue her studies in frailty at Dalhousie 
University, Halifax, Nova Scotia (2007 – 2009). Here, she 
was able to test hypotheses regarding the determinants and 
manifestations of frailty through the interrogation of large 
datasets. She has published widely on the inflammatory 
aetiology of frailty, the difficulties of measuring frailty in 
clinical practice and the relationships between frailty and 
obesity, smoking, socioeconomic status and exercise. 
Her expertise in the field of frailty has been widely 
recognized.
Professor David Johnson 
MB BS (Hons) PhD DMed (Res) FASN FRACP PSM
DHP Chronic Disease and Ageing Theme Leader
Professor Johnson is the Director of the Metro South and 
Ipswich Nephrology and Transplant Service and the Medical 
Director of the Queensland Renal Transplant Service at 
Princess Alexandra Hospital (PAH), Professor of Medicine 
and Professor of Population Health at The University 
of Queensland. He is also the Chair of the Queensland 
Statewide Renal Clinical Network, the CARI guidelines 
Working Parties on Peritoneal Dialysis Adequacy, Evaluation 
of Renal Function and Management of Early CKD, the 
Kidney Check Australia Taskforce and Deputy Chair of the 
Australasian Kidney Trials Network based at PAH, Founding 
Member of the NHMRC endorsed Cardiovascular and Renal 
Centre of Clinical Research Excellence, Member of the 
ANZDATA Registry Peritoneal Dialysis Working group and 
International Society of Peritoneal Dialysis Councillor.
He has published over 480 original manuscripts in peer-
reviewed journals and presented over 330 abstracts at 
national and international scientific meetings. He has won 
numerous research awards for his clinical and basic science 
studies. In 2005, he was awarded the TJ Neale Award by 
the Australian and New Zealand Society of Nephrology for 
“outstanding contributions to nephrologic science.”  
Dr Warren Joubert
MBBCh FRACP 
Dr Warren Joubert has been a consultant medical oncologist 
at the Princess Alexandra Hospital since 2007.  
His research interests include gastro-intestinal cancer and 
sarcoma. 
Chairs and Presenters
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Associate Professor  
Paula Marlton
MBBS (Hons 1) FRACP FRCPA
Associate Professor Paula Marlton is the Head of Leukaemia 
and Lymphoma Services at the Princess Alexandra Hospital 
where she is also Deputy Director of Haematology.  Her 
previous appointments include three years at the MD 
Anderson Cancer Centre in Houston, Texas.  She has extensive 
experience in clinical research including the role of principal 
investigator for national multi-centre trials and supervisor of 
molecular translational research associated with trials.  She 
was the founding Chair of the Australasian Leukaemia and 
Lymphoma group (ALLg) Laboratory Science Committee and 
has established and continues to direct the ALLg Tissue Bank. 
She serves on the QIMR Council, the Board of the Leukaemia 
Foundation of Queensland and is involved in a wide range of 
other academic and advisory services as well as maintaining 
a busy clinical practice. 
Professor Jennifer Martin
MBChB MA (Oxon.) FRACP PhD gAICD
Professor Jennifer Martin  is Head of the PA Southside Clinical 
School and a physician at the Princess Alexandra Hospital.  
She has been involved in teaching, training and curriculum 
development for medical students for 20 years and is 
currently the teaching and learning representative in clinical 
pharmacology for the College of Physicians.  Her current 
research portfolio includes a multidisciplinary and multi-
institution medicines research group in the Translational 
Research Institute.
She is also an economics graduate from Oxford University 
and has used this experience to guide pharmacology 
research and serve on the Pharmaceutical Benefits Advisory 
Committee, the Economic Subcommittee of the PBAC and 
other government committees examining appropriate 
allocation and use of pharmaceuticals.
Professor Michael McGuckin
BSc MSc (Hons) PhD
Professor Mike Mcguckin is an NHMRC Principal Research 
Fellow and is Deputy Director (Research) at the Mater 
Research Institute – The University of Queensland within 
the new Translational Research Institute in Brisbane, where 
he leads the Mucosal Diseases Research group.  He has 
authored over 125 scientific publications.  His research 
is currently focused on mucosal infection and chronic 
inflammation in the gastrointestinal and respiratory tracts 
with particular interests in the role of secreted and cell 
surface mucin glycoproteins in host defense from infection 
and inflammation.  He has a strong interest in the role of 
protein misfolding and ER stress in secretory cells in chronic 
inflammatory disease, including diabetes.  
He has served as the lead member of the Academy of the 
Australian National Health and Medical Research Council 
for gastroenterology.  He chairs the Mater Research 
Committee, and serves on the Research Committees of 
the gastroenterology Society of Australia, University of 
Queensland Faculty of Medicine and Biomedical Sciences, 
and the Translational Research Institute.  
Professor Colleen Nelson
BSc (Hons) PhD
Professor Nelson is the founding Executive Director of the 
Australian Prostate Cancer Research Centre – Queensland, 
the Chair of Prostate Cancer Research at Queensland 
University of Technology, and a member of the Translational 
Research Institute caucus.
Professor Nelson is also the founder and Director of the 
Australian-Canadian Prostate Cancer Research Alliance, an 
initiative developed to coordinate national and international 
network interactions of more than 200 prostate cancer 
scientists and clinicians in Australia and Canada, facilitating 
access to state-of-the-art infrastructure and clinical trials to 
assist in the translation of a wide range of discoveries in both 
countries.
In 2010, Professor Nelson was instrumental with Princess 
Alexandra Hospital urology and oncology colleagues in the 
establishment of the PAH Multi-disciplinary team clinic for 
advanced prostate cancer.
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Professor Ken O’Byrne
MD 
DHP Lung Cancer and Leader, PAH Phase 1  
Clinical Trials Unit
Dr Kenneth O’Byrne took up the positions of Eminent 
Consultant Medical Oncology position at the Princess 
Alexandra Hospital and Professor of Health Sciences at QUT 
in 2013.  He was clinical director of the HOPE directorate at 
St James’s Hospital and a clinical lecturer at Trinity College, 
Dublin.
Dr O’Byrne has a particular interest in the management 
of thoracic malignancies.  His research focuses on the 
identification of novel biomarkers and novel targeted therapy 
in lung cancer and mesothelioma.  Ken has published over 
200 manuscripts in peer reviewed books and journals and 
has led over 100 clinical trials.
Associate Professor  
Ben Panizza
MBBS MBA FRACS MAICD
DHP Head and Neck Cancer Stream Leader  
within the Comprehensive Cancer Centre
Associate Professor Panizza is the Chairman of 
Otolaryngology, Head and Neck Surgery at the Princess 
Alexandra and Logan Hospitals, responsible for the 
Departments clinical delivery, teaching and research. He is 
the founder and current Co-Director of the Queensland Skull 
Base Unit and the immediate past President of the Australian 
and New Zealand Head and Neck Cancer Society.  
He is actively involved in Head and Neck cancer surgery with 
a special interest in skull base malignancy. He has recently 
been appointed as Director of the Queensland Head and Neck 
Cancer Centre which links the Head and Neck Cancer Services 
at PAH to related research at the Translational Research 
Institute and QIMR-Berghofer.  He is a regular contributor to 
the scientific literature and sits on the Editorial board of a 
number of ENT and Head and Neck Journals.
Associate Professor  
Sandro Porceddu
BSc MBBS (Hons) FRANZCR MD
Associate Professor Sandro V Porceddu is a Senior Radiation 
Oncologist at the Princess Alexandra Hospital, and Associate 
Professor with the University of Queensland. His main clinical 
and research interests are in the field of head and neck, and 
skin cancer.  
He is the current president of the Clinical Oncology Society of 
Australia and Trans Tasman Radiation Oncology group.  He 
serves on the boards of Cancer Council Australia and Faculty 
of Radiation Oncology (RANZCR), and is on the UICC TNM 
Staging Classification International Expert Panel for Head and 
Neck, and Skin Cancer.
Professor Elizabeth Powell
MBBS (HONS 1) PhD FRACP FRCP 
Professor Powell is an Eminent Staff Specialist in Hepatology 
at the Princess Alexandra Hospital and Director of The 
University of Queensland Centre for Liver Disease Research. 
In collaboration with her colleagues, Professor Powell 
established an internationally recognised liver research group 
which is making significant contributions to the study of liver 
disease.  To date, this Liver Research Program has helped 
to shape two new paradigms; the importance of metabolic 
risk factors in the progression of chronic liver diseases, and 
more recently proposing altered hepatic regeneration and the 
ductular reaction as a potential driver of hepatic fibrosis.  The 
group has a strong track record in successful NHMRC Project 
grant funding and in fostering health and medical research 
training in Queensland.
Professor Powell currently holds an NHMRC Practitioner 
Fellowship (third renewal) and a Queensland government 
Health Research Fellowship.
Chairs and Presenters
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Professor John Prins
MBBS PhD FRACP
DHP Board Member
Professor John Prins is Director/CEO of the Mater Research 
Institute-UQ, Senior Endocrinologist at Princess Alexandra 
Hospital, and Professor of Endocrinology at The University of 
Queensland. He is also a Director of the Metro South Hospital 
and Health Service. 
He undertook his clinical training in Endocrinology and his 
PhD in adipose tissue biology in Australia. He then undertook 
a 4-year post-doctoral appointment at The University of 
Cambridge, UK. In 1998 he returned to Brisbane, Australia, 
where he established an active research programme 
undertaking clinical trials in Obesity and Diabetes and 
investigating various aspects of adipose biology, insulin 
signalling, and adipogenesis. He has supervised over 20 PhDs 
and over 30 Endocrinology trainees. 
He has received over $15M in research funding and has 
published over 140 research publications with a total of 
10,000+ citations. He sits on numerous grant review and 
advisory committees for the NHMRC, NgOs and Industry.
Associate Professor  
Nick Saunders
BSc (Hons) PhD
Associate Professor Nicholas Saunders trained as a 
pharmacologist at the University of Western Australia 
under the supervision of Professor Rodney Minchin and 
Professor Ken Illett.  He was then awarded a Fogarty Visiting 
Fellowship to pursue postdoctoral studies at the National 
Institute of Environmental Health Sciences in the USA 
under the supervision of Professor Anton Jetten.  In 1993, 
he was approached by Professor Ian Frazer to return to 
Australia and set up the Epithelial Pathobiology group. 
Since establishing his research group, he has attracted 
over $10 million in competitive research funding and has 
been the recipient of a Lions Medical Research Foundation 
Senior Research Fellowship and a garnett Passe and Rodney 
Williams Memorial Foundation Principal Research Fellowship.  
Dr Saunders is also an Adjunct Associate Professor with 
the School of Biomedical Sciences at The University of 
Queensland.
Associate Professor Ian Scott
MBBS FRACP MHA Med
DHP Evidence and Innovation Theme Leader
Associate Professor Ian Scott is a consultant physician in 
internal medicine and Director of the Department of Internal 
Medicine and Clinical Epidemiology at the Princess Alexandra 
Hospital in Brisbane. He is an Associate Professor of Medicine 
at The University of Queensland, an Adjunct Associate 
Professor of Medicine in Epidemiology and Preventive 
Medicine at Monash University and a Research Associate 
with the Centre for Research Excellence in Patient Safety in 
Melbourne. He is a current member of Queensland Health 
Patient Flow and Clinical Redesign Executive Committee and 
the Quality Expert Advisory group of the Royal Australasian 
College of Physicians.
He has led large-scale multi-site quality improvement 
programs targeting in-hospital and post-hospital care. 
Research and teaching interests include health services 
evaluation, evidence-based medicine, quality improvement 
and knowledge transfer. He has authored over 130 papers in 
peer reviewed Journals.
Professor Peter Soyer
MD FACD
DHP Epithelial Malignancy Stream Leader  
within the Comprehensive Cancer Centre
Professor Soyer is an academic dermatologist with over 
30 years of experience in the field. He was appointed as 
the inaugural Chair in Dermatology by The University of 
Queensland (UQ) in 2007 and as Director of the Princess 
Alexandra Hospital (PAH) Dermatology Department in 2008. 
He has a strong focus on translational skin cancer research.
Professor Soyer is internationally recognised in the field of 
dermatology with particular expertise in dermatopathology, 
dermatooncology and is recognised as a world leader in 
dermoscopy and clinico-pathologic correlation of melanocytic 
proliferations. In recent years his scientific activities have 
broadened to include teledermatology, teledermatopathology 
and teledermoscopy and he is CIE on a recently awarded 
NHMRC Centre for Research Excellence in Telehealth.
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Associate Professor  
Tony Stanton 
Associate Professor Tony Stanton is a cardiologist with a 
special interest in non-invasive cardiovascular imaging. 
He has a particular interest in the interaction between 
multisystem disease and cardiovascular function. 
He practices at the Princess Alexandra Hospital and Ipswich 
Hospital. He is the Director of the Cardiovascular Imaging 
Research group at The University of Queensland.
Professor Michael Stowasser
MBBS (Hons 1) PhD FRACP
Professor Michael Stowasser is the Director of the 
Hypertension Units, and Co-Director of the Endocrine 
Hypertension Research Centre (EHRC), at greenslopes and 
Princess Alexandra Hospitals, University of Queensland 
School of Medicine.
He has over 20 years of clinical research experience in 
pathogenesis and management of hypertension and 
especially of endocrine varieties including primary 
aldosteronism. He has served as Executive Committee 
Member of the High Blood Pressure Research Council of 
Australia (1998-2004; Secretary 2001-2004), member of 
the National Heart Foundation High Blood Pressure and 
Vascular Disease Advisory Committee (1998-) and organising 
committee member (including convenor) on several medical 
conferences. He is a former member of the editorial board 
for the Journal of Clinical Endocrinology and Metabolism and 
currently Co-Editor for the Journal of Human Hypertension.
Professor Ranjeny Thomas
MBBS MD FRACP 
Professor Thomas is a graduate of the University of Western 
Australia.  She received her MBBS in 1984, and then trained 
in Perth as a rheumatologist.  She commenced a research 
fellowship with Peter Lipsky at Southwestern Medical Center, 
University of Texas in 1990, where she first identified and 
characterised human circulating dendritic cell precursors.
Her research is focussed on the study of autoimmune 
disease and restoration of tolerance.  Through this work, 
she developed and tested the first rheumatoid arthritis 
vaccine.  She has also contributed major insights into the 
pathogenesis of spondyloarthropathies and autoimmune 
diabetes, leading to the development of disease biomarkers 
and therapeutic strategies.  She is founder and a director 
of the spin-off company, Dendright, which is developing 
vaccines to suppress autoimmune diseases. 
Associate Professor  
Damien Thomson
MBBS PhD FRACP
Associate Professor Thomson is a Pre-eminent Staff Specialist 
and Director of Medical Oncology, Division of Cancer Services 
at Princess Alexandra Hospital and Associate Professor of 
Medicine at Queensland University, Brisbane. 
He is a member of the Queensland Hospitals Medication 
Advisory Committee, the Oncology Education Committee of 
the Cancer Council Australia and the Editor in Oncology for 
the Internal Medicine Journal. He has an extensive research 
interest in melanoma and germ cell tumours and more 
recently onco-geriatrics.
Chairs and Presenters
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Professor Zee Upton
BSc. (First Class Hons) PhD
DHP Board Member
Professor Zee Upton is the Assistant Dean (Research) in the 
Queensland University of Technology Faculty of Health. In 
this role she guides strategic direction and research capacity 
building in the Faculty.
Professor Upton’s own research is focussed on tissue repair 
and regeneration, with an emphasis on chronic wounds. 
Since the award of her PhD in Biochemistry in 1994 she has 
developed a significant record of innovative and quality 
scientific research that has yielded $27+ million in research; 
110+ publications; 11 patent applications; the receipt of many 
awards, including most recently the 2013 Banksia Scientific 
Regenerative Medicine Award and the 2011 Queensland Life 
Sciences Industry Award; and the establishment and listing of 
a biotechnology company, Tissue Therapies Ltd, on the ASX. 
She leads the establishment of the $110+ million Wound 
Management Innovation CRC in 2010.
Associate Professor  
Paul Varghese
MBBS Pg Dip PH FRACP FANZSgM
Associate Professor Paul Varghese is the Director of geriatric 
Medicine at the Princess Alexandra Hospital. He studied 
at The University of Queensland and trained as a general 
Physician before completing his fellowship in geriatric 
Medicine in 1992. He practices in clinical geriatric medicine 
with clinical interests in the areas of amputees, dementia, 
falls and the acute care of the elderly. He is actively involved 
in undergraduate and post graduate teaching. 
He is current Chair of the State Falls Injury Prevention 
Collaborative, is Chair of the Older Persons Health Network 
and attends the Clinical Senate.  He sits on a number 
of clinical reference groups at both a State and Federal 
level.  His research interests include falls, clinical database 
design, tele-geriatrics and the management of patients with 
dementia.
Dr John Wakefield
MB CHB MPH (Research) FRACgP FACRRM FRACMA
Dr Wakefield is Executive Director Medical Services (EDMS) 
Children’s Health Queensland and Adjunct Professor of Public 
Health at Queensland University of Technology.
He has over 20 years of experience in clinical and 
management roles in rural, regional and tertiary public 
sectors in Queensland.  After completing a Fellowship under 
Dr Jim Bagian, at the National Center for Patient Safety 
of the VA Health System in the United States. In 2004 he 
established the Queensland Health Patient Safety Centre, 
which he led until late 2012.  
He is actively involved in national efforts to improve patient 
safety in partnership with the Australian Commission for 
Safety and Quality in Healthcare.  He chaired the National 
Open Disclosure Pilot Project and regularly teaches Open 
Disclosure and other patient safety curricula.  His research 
interests include patient safety culture, safety performance 
measurement and Open Disclosure. In November 2013, 
he took up the position of EDMS at Children’s Health 
Queensland.
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Associate Professor  
Euan Walpole
MBBS (Hons) FRACP
DHP Comprehensive Cancer Centre Theme Leader
Dr Euan Walpole received his M.B.B.S (Hons) from The 
University of Queensland in 1980.  After four years at the 
Princess Alexandra Hospital (PAH) Brisbane, Dr Walpole was 
a registrar in Haematology and Medical Oncology at the Peter 
McCallum Cancer Institute Melbourne before returning to 
the PAH as a Medical Oncologist.  He undertook a visiting 
Fellowship in Oncology at the Montefiore Medical Centre / 
Albert Einstein Cancer Center, New York.  He currently holds 
the position of Medical Director – Cancer Services for the 
PAH and Metro South Health Service.  He is also an Associate 
Professor at The University of Queensland, Honorary 
Associate of the NHMRC Clinical Trials Centre, University of 
Sydney. He visits Mt Olivet Hospital and private hospitals.
Noted appointments include Chairmanships of the 
Queensland Cancer Fund Medical and Scientific Advisory 
Committee, Medical Oncology group of Australia, Specialist 
Advisory Committee in Medical Oncology of the Royal 
Australasian College of Physicians and membership of 
Specialties Board.
Associate Professor  
Jon Whitehead
BSc PhD
After completing his PhD at the University of Liverpool (UK) 
in 1994, Dr Whitehead moved to the University of Cambridge 
(UK) where he began work in the area of insulin signalling, 
insulin resistance and obesity.  In 1999 he secured an 
International Travelling Fellowship from the Welcome Trust, 
taking up a position at the Institute for Molecular Bioscience 
at The University of Queensland (UQ), then the Diabetes & 
Obesity Research Program at the garvan Institute of Medical 
Research in Sydney.  
In 2002 he returned to UQ to take up an independent position 
as a Lions Senior Medical Research Fellow.  In 2008 he was 
awarded an NHMRC Senior Research Fellowship and relocated 
to the Mater Research Institute in early 2010.
Associate Professor  
Ingrid Winkler
PhD
Associate Professor Ingrid Winkler is a Senior Research 
Fellow and head of the Stem Cells and Cancer group at Mater 
Research Institute - University of Queensland, Brisbane, 
Australia. 
Her research seeks to understand how normal and malignant 
Haematopoietic Stem Cells are regulated by their local 
microenvironment.
Over the course of her career, Dr Winkler has produced 49 
peer-reviewed articles. Most recently publishing a landmark 
study in Nature Medicine 2012, describing a key component 
of the bone marrow vascular niche regulating haematopoetic 
stem cell self-renewal and chemo-sensitivity. In the last 
year her research has been selected among the ‘Ten of the 
best’ in Australia (NHMRC 2013) complementing an earlier 
‘Outstanding Achievement Award’ from Australia’s NHMRC 
(2011).   
Professor Ross Young
BSc. MSc. Dip Clin Psych PhD
DHP Board Member
Professor Ross Young was appointed Executive Dean, Faculty 
of Health in 2013.  He was the Executive Director of Institute 
of Health and Biomedical Innovation at the Queensland 
University of Technology from 2006 -2012.  He is also a 
Visiting Research Fellow at the Alcohol Research Center, 
University of California, Los Angeles and a Senior Clinical 
Psychologist at the Alcohol and Drug Assessment Unit, 
Princess Alexandra Hospital, Brisbane.  
His research interests lie in the integration of psychological 
and biological risk factors in mental illness.  His research 
includes work in substance misuse, schizophrenia, anxiety 
disorders and more broadly in behavioural medicine.  This 
includes work in pharmacogenomics and the development of 
personalised medicine via the use of diagnostic gene chips.  
He is widely published and has over 190 published papers in 
genetic, medical, psychiatric and psychological journals.
He serves on a number of Boards including Cancer Council 
Queensland, gallipoli Medical Research Foundation and 
Mantle (Pty) Ltd.
Chairs and Presenters
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Speaker Synopses
Regents Professor David Alberts 
Building a comprehensive Cancer Center in the 21st Century
It is a Herculean task to build a National Cancer Institute 
Designated Comprehensive (academic) Cancer Center from 
scratch in the U.S and I have been through that.  However, 
comprehensive Centers can be assembled that significantly 
benefit the quality of care of cancer patients.   
The basic building blocks to establish such a comprehensive, 
academic Cancer Center include the following: 
1.  An outstanding group of scientists with a minimum of $10 
million of annual direct cost research funding
2.  A strong, multidisciplinary group of surgical, radiation, 
medical and nurse oncologists
3.   A dedicated and continuous flow of new cancer cases 
4.   A network of hospitals and healthcare providers that can 
enhance tertiary cancer patient referrals and provide an 
opportunity for both outreach education and training
5.  But this task can be accomplished with the combined 
support of healthcare administrators, specialty 
oncologists, basic and translational scientists, politicians 
and philanthropists and years of extremely focused work 
by everyone.  
Dr Victoria Atkinson 
Therapy for melanoma has changed rapidly in the past 
few years, and there is now systemic options which can 
improve survival for patients with advanced disease. This 
discussion will provide an overview of targeted therapy and 
immunotherapy for advanced melanoma.
Professor Jeff Coombes
Regular exercise can help protect against heart disease 
and stroke, high blood pressure, type 2 diabetes, obesity 
and mental health issues. The physiological mechanisms 
underpinning the many health benefits of exercise are multi 
factorial including lowering cardiovascular disease risk 
factors, improving vascular and heart function and glucose 
homeostasis. The cellular benefits of exercise that lead to the 
physiological benefits are less understood. This presentation 
will discuss the evidence that exercise may improve the 
ability to regulate cellular redox homeostasis and this may be 
a central controller for biochemical adaptations. Specifically, 
the effect of exercise on NRF2 will be examined along with 
clinical biomarkers that could be useful for assessing the 
ability to maintain redox control.    
Dr Jim Coward 
Despite the emerging evidence to support the importance of 
inflammation in the recurrence of these diseases, there is a 
paucity of translational studies that focus on manipulating 
this process in order to prolong survival. IL-6 is a pleiotropic 
cytokine that has a significant role in the ovarian cancer 
microenvironment and mediates processes relating to tumour 
proliferation, invasion, angiogenesis and chemo-resistance 
that all lead to poor prognosis. We have conducted preclinical 
and in silico experiments combined with a Phase II clinical 
trial using the anti-IL-6 antibody siltuximab in patients with 
advanced platinum resistant high grade serous (HgSC) and 
clear cell (OCCC) subtypes of Epithelial Ovarian Cancer (EOC).
These studies confirm that IL-6 stimulates inflammatory 
cytokine production, tumour angiogenesis and the tumour 
macrophage infiltrate in EOC. In addition, both paracrine 
and autocrine actions can be inhibited by a neutralising 
anti-IL-6 antibody and can exert significant clinical benefit. 
Hence, targeting inflammation in HGSC and OCCC may prove 
a useful strategy in extending survival and could potentially 
complement standard chemotherapy. Our current in vitro and 
ex vivo studies analyzing the biological effects exerted by 
combinatorial and sequential regimens of anti-IL-6 therapies 
with cytotoxic agents are also providing useful insights for 
future clinical trial development.
Professor Josephine Forbes 
Type 1 diabetes occurs in early life and its incidence in 
Australia is increasing as a result of unknown environmental 
contributors. In this presentation, we will outline how 
modifications of proteins seen in our modern food chain may 
be influencing risk for type 1 diabetes via interactions with our 
immune system.
Professor Ian Frazer 
Public health research has given us information to  reduce 
the cancer burden,  and the cost of cancer care to  the 
community, by 30% through behaviour modification. Vaccines 
to prevent cancer caused by viral infection could, if deployed 
globally,  reduce cancer by a further 10% while environmental 
measures found achieve a further 20% reduction.  The value 
of early detection of breast and bowel cancer is considerable, 
while utilisation of  our knowledge of the cancer genome  will 
enable personalised cancer treatments, with better side effect 
profiles , for some common cancers. Unless we can make use 
of  all of these interventions made possible through research, 
cancer is likely to become the commonest cause of death 
across the globe by 2050. 
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Professor Devinder Gill 
Personalized medicine is about the right treatment for the 
right condition in the right patient. The future of personalised 
medicine is increasingly involving genomics, the study of 
information from a patient’s entire genetic sequence. DNA 
sequencing is becoming faster and more sophisticated, 
making it easier to determine the best treatment based on 
genetics of the disease and the individual. This approach 
and recent advances in the biology of cancer is leading to 
treatments that target cancer-causing molecules and are 
being seen as beginnings of a new era in medicine. These 
recent therapeutic advances and the current research in 
blood cancer will be presented.
Dr Nick Graves 
The talk is about economics and the study of how society 
should respond to scarce resources. The importance of 
good decisions is stressed and reviewed against the current 
incentives that powerful agents in health services might 
face. Examples of some poor decisions in health services 
are provided, with supporting data. The potential for health 
services researchers to provide information about how 
to improve decisions is discussed, but the question how 
we change incentives for powerful agents to choose good 
services is left open for a discussion.
Professor Len Gray
When contemplating the translational pathway, many 
contemplate the translation of biological discoveries into 
clinical practice through drugs and vaccines. However, the 
practice of medicine is likely to also be revolutionised by new 
technologies and knowledge systems. Over the past 10 years, 
the Centre for Research in geriatric Medicine has developed 
mechanisms to potentially revolutionise the practice of 
assessment and care delivery.  
The combination of new knowledge systems based on the 
application of structured assessment into clinical decision 
support systems, built on software platforms, connected via 
the internet, together with video-conferencing systems, is 
allowing traditional geriatric medicine practice to be offered 
in an array of inaccessible locations, such as small rural 
hospitals, nursing homes and soon the patients’ homes. 
These systems almost eliminate the need for direct contact 
between the specialist and the patient to achieve successful 
results.
Professor Janet Hardy 
About 10% of cancer patients have pain that is refractory 
to standard treatment with opioids and co-analgesics. The 
anaesthetic agent ketamine is often used in this scenario.  
A randomised placebo controlled trial has shown that not 
only is ketamine no more effective than placebo but that it 
is considerably more toxic. Following publication, this study 
was subject to a wide dissemination program. A survey of 
clinicians has shown that over 2/3 of respondents have 
changed practice in response,  but that many still prefer to 
believe in their own experience rather than the results of a 
RCT. 
Associate Professor Carmel Hawley 
Appropriately designed and powered clinical trials are central 
to the registration of new agents/ devices, development 
of new indications for existing treatments, comparison of 
different strategies, and for the effective, efficient and safe 
translation of these therapeutic developments.  Change 
in needed to increase quality and efficiency: agreement 
regarding appropriate trial designs, endpoints and 
implementation approaches; acknowledgement of, and 
guidelines for trial oversight based on the risks and benefits 
to participants; novel trial designs; and greater collaboration 
between academia, regulators, and industry, from all regions 
of the world.  Most importantly the academic community 
needs to reclaim leadership from industry to more effectively 
meet the needs of our patients. 
Dr Ruth Hubbard
Older people in hospital are at high risk of prolonged 
hospital stays, institutionalization and death. This increased 
vulnerability to adverse outcomes is commonly referred to as 
frailty. A project currently underway in the Centre for Research 
in geriatric Medicine is investigating whether a precise 
measure of frailty status could be integrated into an existing 
assessment system. This would have the potential to target 
care more appropriately, providing a clearer strategy to meet 
the needs of vulnerable older people.
Professor David Johnson
It is currently recognised that evidence-based best practice 
is frequently not translated into actual clinical practice 
resulting in suboptimal clinical outcomes for patients. This 
presentation reviews significant improvements that have 
been recently made in Australian nephrologic practice and 
clinical outcomes through targeted strategies addressing 
generation of high level clinical evidence, incorporation of 
evidence into guidelines, implementation of guidelines into 
clinical practice and monitoring patient outcomes through a 
national key performance indicator project.
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Professor Jennifer Martin  
The ‘personalised medicine’ revolution has not lived up 
to its promise of improving survival in cancer. There are 
several issues to explain this – the neglecting of the complex 
biology of ‘solid’ tumours and how this changes with time 
and treatments (eg other chemotherapy or radiation), the 
relationship of a single, perhaps not pivotal gene being 
switched on or off amongst many others, the issue of toxicity, 
and a failure to appreciate the complex biology around drug 
efficacy and toxicity. This presentation will discuss methods 
to change ‘group think’ around issues using personalised 
medicine as an example, and how by rethinking the paradigm 
using current methodologies  and data better can be used in 
a very cost-effective and timely way to improve health care.
Professor Mike McGuckin 
We have discovered that the cytokine, IL-22, is an 
endogenous suppressor of oxidative stress in pancreatic 
beta cells.  In diabetes beta cells experience oxidative 
stress and this is thought to be central to the inability to 
produce sufficient insulin to control blood glucose. Treatment 
of diabetic mice with IL-22 restores glycaemic control, 
suppressing hyperinsulinaemia, hyperproinsulinaemia and 
insulin resistance. Our major challenge now is to translate 
these findings into new therapies for diabetes and potential 
approaches and required clinical and preclinical studies will 
be discussed.
Professor Victor Montori
Minimally Disruptive Medicine
Is it possible that the health systems we construct to improve 
outcomes could be overwhelming patients? What is the 
work of being a patient? Minimally disruptive medicine is 
an approach that respects patients’ capacity and seeks to 
advance their goals while imposing the smallest possible 
footprint on their lives.
Placing patients at the center of our research and our practice
What does it mean to put patients at the center of research 
and what happens when we do not do this? What are the 
implications for a patient-centered practice? Using examples 
from research and practice in diabetes we will explore the 
opportunities of patient-centered healthcare. 
Professor Colleen Nelson 
Androgen-regulated pathways promote proliferation, 
differentiation and survival of benign and malignant prostate 
tissue. Androgens elicit these biological consequences 
acting through the androgen receptor, to result in both the 
activation and repression of various cellular and physiological 
pathways. Androgen Targeted Therapies (ATT) are widely 
used to exploit this dependence in advanced prostate cancer 
patients. 
Although targeting the androgen axis has clear therapeutic 
benefit, the beneficial effect is counter balanced by 
predictable adaptive responses which concurrently result 
in the activation of tumour promoting physiological and 
biological pathways. These activated pathways in response 
to ATT collectively collaborate to promote cancer progression 
and treatment resistance. Insights from the reproducible 
activation of these adverse pathways which underpin 
treatment resistance  offers  rationalized development for co-
targeting therapies to be used in combination or in sequence 
with ATT to improve cancer control in advanced prostate 
cancer. 
Professor Ken O’Byrne
Personalised medicine is the current approach used for the 
development of novel targeted therapies that ensure that the 
right person gets the right drug with the highest likelihood of 
success. This approach applies to drugs that target specific 
driver oncogenic mutations, gene amplifications and over 
expressed proteins. The decision determining which drug 
is given is now  often dependent on the use of a molecular 
diagnostic test to identify those patients most likely to benefit 
from that specific therapy. The judicious use of these tests 
therefore ensures that ensures that those patients unlikely to 
benefit are likewise not exposed to agents that could cause 
side-effects. Furthermore molecular diagnostics can ensure 
that expensive drugs are used in the most cost effective 
manner possible.
Associate Professor Sandro Porceddu 
Laboratory and clinical research have confirmed tumour 
hypoxia (oxygen starvation) is a major determinant of poor 
cure rates in patients affected with certain head and neck 
cancers. State-of-the-art Positron Emission Tomography (PET) 
scanning can now detect tumour hypoxia in vivo, allowing 
testing of specific anti-hypoxia cancer drugs, in combination 
with radiotherapy, in an attempt to improve cure rates without 
the need for radical surgery. Clinical trials conducted at the 
PAH, as part of the Trans Tasman Radiation Oncology group 
(TROg) trials, have shown promise with this approach. 
Emerging data and the commencement of new trials will be 
presented.
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Associate Professor Ian Scott
In an era of financial constraints and government intentions 
to cap or reduce expenditure on healthcare, the ability of 
the healthcare system to continue to provide safe, effective, 
evidence-based clinical care to all who need it is under threat. 
Overcoming this challenge requires a reappraisal of what 
constitutes effective care at the level of populations, a greater 
role of informed citizens in making autonomous decisions 
about what care should be provided, and a clear definition 
of what constitutes value of healthcare in terms of outcomes 
achieved for costs incurred. 
Professor Peter Soyer 
The widespread use of smartphones has opened new 
pathways for medical professionals and consumers 
(traditionally called patients) screening and monitoring for 
health concerns. Dermatology is potentially well-suited to 
teledermatology applications because diagnosis is largely 
made by visual inspection. Specific to skin cancer early 
detection dermatoscopes have been developed which can 
be attached to smartphones (together forming a mobile 
teledermatoscope) allowing consumers to take magnified 
images of skin lesions and to send these images for specialist 
advice.
We foresee that in the near future there will be an icon on the 
screen of all cellular phones allowing telehealth consultations 
including early diagnosis of melanoma “by one click”.
Mobile telehealth has the potential to become a disruptive 
innovation in healthcare.
Associate Professor Tony Stanton
Echocardiography is a well-established ultrasound test 
for evaluating the contraction of the heart. It has grown to 
become one of the commonest tests requested in medicine 
as it is a powerful predictor of patient events and outcome. 
This talk will discuss echocardiographic strain, one of the 
new techniques available to us in echocardiography, and how 
strain is able to provide us with even more powerful data to 
help evaluate cardiac function. This data will allow us to more 
accurately assess patients’ cardiovascular risk both now and 
in the future.
Professor Michael Stowasser
Primary aldosteronism (PA) is a disease in which the adrenal 
glands produce excessive amounts of salt-retaining hormone 
(aldosterone) leading to high blood pressure (hypertension). 
PA is the most common potentially curable and specifically 
treatable form of hypertension with possibly over 100,000 
Australians affected, most of them yet to be detected. This 
project will examine a new way of diagnosing PA which 
appears to be highly accurate, yet much quicker, cheaper and 
more convenient than the current “gold standard” approach, 
potentially resulting in major cost savings ($2000-2500 per 
test) and many more patients with PA diagnosed and enjoying 
the benefits of optimal specific treatment.
Professor Ranjeny Thomas 
Commercialization is the only way to get a novel discovery 
out of the research lab to benefit patients. In 2003, my team 
and I discovered that the body’s immune response could be 
“re-educated” to turn-off, rather than react to a self-antigen 
responsible for an autoimmune disease, such as rheumatoid 
arthritis. By targeting the cause of autoimmune disease, 
rather than treating the symptoms, we realized that this 
type of immunotherapy offers the potential for long-lasting 
treatment by working with the body’s own immune system to 
fight the disease. 
Furthermore, targeting a therapy to disease-specific antigens 
would be safer than global immune suppression. Both 
of these advantages position such a therapy for eventual 
disease prevention in subjects at risk. Hence, the Uniquest 
biopharmaceutical start-up company, Dendright Pty Limited, 
was established in 2005 to develop novel immune tolerizing 
drugs for the treatment of autoimmune disease. However, 
making a discovery is just the beginning: the hard work lies 
ahead to secure funding to translate the research and bring it 
to the benefit of patients. 
The road started with a patent application for a cell-based 
therapy in 2002. Negative market feedback informed 
research in collaboration with Nigel Davies at the School 
of Pharmacy to reformat the original therapy from cell-
based to an injectable particulate formulation, followed 
by a separate patent application in 2006. In August 2013, 
Dendright signed a R&D collaboration and option to license 
agreement with US-based Janssen Biotech, Inc. to develop 
and commercialize Dendright’s tolerizing immunotherapy in 
the field of rheumatoid arthritis. In this talk, I will map the 
journey to commercialization and the lessons we have learnt 
and continue to learn along the way.
Speaker Synopses
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Associate Professor Paul Varghese 
Attaining practice change in a large organisation poses 
many challenges.  This presentation outlines the experience 
with the Confused Older Persons in the Emergency 
Department(COPED) and the Falls Assessment and 
Management Plan (FAMP) projects which were auspiced 
under the Older Persons Clinical Network and the Falls Injury 
Prevention Collaborative respectively.  Recent changes 
to the corporate structure within Queensland Health, the 
geographical challenges with practice variation across rural 
and metropolitan services and the difficulties encountered 
in collaborating with different craft group are explored.  
Resistance to implementation of best practice within a 
complex health system is discussed.
Dr John Wakefield 
This presentation will explore the value of research from a 
health service perspective. What are the current challenges 
facing health service delivery in 21st century? To what extent 
does the current investment in research help address these? 
The case for change in prioritising research strategy and 
funding. Balancing the research investment to ensure that 
evidence is reliably translated into practice. 
Associate Professor Euan Walpole 
Mammographic screening was introduced in Queensland in 
2001 to reduce breast cancer mortality. Worldwide interest 
in the results of mammography has raised questions 
about the real impact. DCIS is believed to be a precursor of 
breast cancer and interventions for this are to prevent the 
development of invasive cancer. Statistics from Queensland 
are discussed compared to international incidence changes 
as well as the treatment impact of the diagnosis of DCIS.
Associate Professor Ingrid Winkler 
In her talk Dr Winkler will present new unpublished data 
describing Acute Myeloid Leukaemia stem cells regulation 
by Bone marrow niches and other research following on from 
the discoveries described in her recent Nature Medicine 
manuscript and potential new strategies to help cancer 
patients better survive chemotherapy.
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Pre-Forum Symposium:
“Research and Innovation Ideas”
The PA Research Foundation 
is pleased to work with 
Diamantina Health Partners 
to support the Pre-Forum 
Symposium: “Research and 
Innovation Ideas”Award
In 1984 the PA Research Foundation 
was established to raise funds for 
groundbreaking, lifesaving research — to 
develop better diagnoses, treatments and 
preventions for some of Australia’s biggest 
health challenges. Each year provides the 
Foundation with new opportunities to fund 
exceptional research projects proposed 
by the many talented and dedicated 
clinicians, scientists, nursing and allied 
health professionals on the Princess 
Alexandra Hospital campus.
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DEVELOPMENT OF NOVEL CLASS OF ERAP INHIBITORS FOR 
TREATING AUTOIMMUNE DISEASES 
Nitish Agrawal
University of Queensland 
Arthritis is the major cause of disability and chronic pain in 
Australia.  One in three Australians has a musculoskeletal 
condition such as back pain, with 2% of people gradually 
develop Ankylosing spondylitis (AS) disease, an inflammatory 
disease that affects primarily the sacroiliac joints & axial 
skeleton (spine).  About 10% of AS cases also develop 
either Inflammatory Bowel disease (IBD), form of intestinal 
inflammation or Psoriasis, a skin disease.  A series of 
genome-wide studies have demonstrated associations of 
M1 aminopeptidases with these diseases.  Functional data 
from ERAP1, ERAP2 genes suggests that the mutations which 
protect from AS, IBD, Psoriasis results in loss of function 
of its encoded protein.  This application focuses on use of 
fluorogenic method for high-throughput screening (HTS) of 
the aminopeptidase inhibitors.  Our protein target-based 
approach will provide a novel class of therapeutics for the 
first time, capable of preventing disease progression in 
AS patients and are likely to be also effective for treating 
Psoriasis and Crohn’s disease.  The success of our proposed 
drug discovery research will boost economic benefits of more 
than 10B$ in Australia.  
WHAT HAVE THE ROMANS EVER DONE FOR US?
Dr Ruth Barker1, Don Morgan2
1 Emergency Paediatrician, Mater Children’s Hospital, Brisbane
 Director Queensland Injury Surveillance Unit
2 Physicist and inventor of Conehead technology for helmets
Helmets have been used for thousands of years to protect the 
human head (skull and contents) from damage.  Despite this, 
we are still struggling to optimise helmet design, production 
and use.
Whilst productivity (production costs, distribution costs, 
sales) in relation to helmets is readily and frequently 
measured, efficacy (in the real world) is not.  Therefore, we 
are regulating design, production and use of helmets, with 
little to no information about efficacy.
This is particularly evident with paediatric helmets, where 
helmet design (fit and impact attenuation) is modelled on 
adult metrics and may not be appropriate for a paediatric 
skull and developing brain.
A collaborative project has been developed between QISU, 
Victorian Injury Surveillance Unit (VISU), Paediatric Research 
in Emergency Departments International Collaborative 
(PREDICT) and industry (Conehead Technology) to correlate 
helmet use (make, model, impact history) and fit in paediatric 
patients presenting to emergency departments with their 
injury patterns (physical examination and imaging) following 
a head impact. This information can be used to inform helmet 
design that can deliver superior fit and impact attenuation.
INNOVATIVE SUPPORTIVE MEALTIME STRATEGIES IMPROVE 
PATIENT NUTRITIONAL INTAKE
Rhiannon Barnes
Princess Alexandra Hospital
Thirty percent of inpatients at Princess Alexandra Hospital 
(PAH) are malnourished, resulting in adverse outcomes 
such as extended length of stays, higher readmission rates, 
reduced quality of life and increased morbidity and mortality 
increasing healthcare costs.  A pilot study implementing 
Encouraging, Assisting and Time to eat (EAT) mealtime 
strategies assessed inpatient experiences at lunchtime pre-
(n=94) and post-intervention (n=86) to reduce interruptions 
and increase assistance improving consumption to reduce 
malnutrition. There were significant increases in mealtime 
assistance (37% pre-intervention vs 63% post-intervention; 
p<0.001).  Significant improvements were also seen with the 
bedside tray being positioned suitably (p<0.001) and free 
from clutter (p<0.001) resulting in increased patient meal 
consumption (p=0.002). 
Implementing EAT across PAH will improve patient meal 
consumption & nutritional status reducing the burden of 
malnutrition with financial benefits associated with reduced 
plate wastage and healthcare costs respectively.  The project 
has support of PAH Nutrition Care, Essence of Care, Falls and 
Pressure Ulcer Committees and involves collaborations with 
nursing, medical, allied health and food services. 
EBC-46: A NOVEL TREATMENT FOR HEAD AND NECK 
SQUAMOUS CELL CARCINOMA
Dr Catherine Barnett, Dr Ryan Adams, Dr Glen Boyle,  
Assoc Prof Ben Panizza, Prof Peter Parsons
Princess Alexandra Hospital, Brisbane, QLD.
Queensland Institute of Medical Research, Brisbane, QLD
Purpose: The five-year survival rate for patients with head 
and neck squamous cell carcinoma (HNSCC) has remained 
at ~50% despite recent advances in surgical technique, 
chemotherapy agents and radiation therapy. EBC-46 is a 
novel drug that induces HNSCC cell senescence in vitro. The 
purpose of this study was to confirm the efficacy and safety 
of intratumoural treatment of HNSCC with EBC-46 in mouse 
models. 
Research and Innovation Ideas
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Methods: Subcutaneous xenografts of different HNSCC cell 
lines were grown in Balb/c (FoxN1-/-) mice and treated with 
intratumoural injection of 30 µg EBC-46 or a control solution.
Results: Treatment with EBC-46 completely ablated the 
HNSCC xenografts via haemorrhagic necrosis and stimulation 
of the innate immune response. No significant adverse effects 
were identified.
Conclusions: EBC-46 effectively and safely ablated HNSCC 
in a mouse model. These significant results provide the 
foundation required for progression to phase 1 clinical trials.
THE FDA APPROVED DRUG PINDOLOL IS A NOVEL TREATMENT 
FOR ALCOHOL DEPENDENCE
Paul Klenowski1, Omkar Laxman Patkar1, Joan Holgate1, Peter 
Molenaar2, Selena Bartlett1
1 Translational Research Institute, Queensland University of Technology, 
Brisbane, QLD
2 Institute of Health and Biomedical Innovation, Queensland University of 
Technology, Brisbane, QLD
Stressors contribute to the development of alcohol 
dependence and medicines such as the anti-hypertensive 
drugs, prasozin and propranolol, which block the effects 
of noradrenaline at beta-adrenoceptors (AR) have shown 
promise as potential therapeutic agents for the management 
of stress-induced alcohol consumption and relapse.  We 
have characterized a series of selective b
1
AR compounds to 
determine their effect on drinking behavior in mice. C57BL/6 
mice  were housed individually in a reverse light-dark cycle 
and given access to 1 bottle of 20% ethanol (v/v) and 1 bottle 
of filtered water for a 2hr period, 5 days a week, 3hrs into 
the dark cycle.  Compounds or vehicle were administered 
via subcutaneous injection after 4 or 12 weeks of ethanol 
exposure.  We show that pindolol, a dual β
1
AR antagonist and 
5HT receptor partial agonist caused a significant decrease 
in ethanol consumption in mice following 12 weeks but not 
4 weeks of ethanol consumption. We are performing further 
mechanistic studies but the data suggest pindolol represents 
a novel therapeutic agent for the treatment of alcohol 
dependence and we have started “proof of concept” clinical 
trials to determine efficacy in humans.
PRE-CLINICAL RHEUMATOID ARTHRITIS – PREDICTION AND 
PREVENTION
Helen Benham1,3, Soi Law1, Lisa Cummins2, Hanno Nel1,  
Helen Pahau1, Matthew Brown1, Helen Roberts6,  
Mark Morrison1, Kristen Radford4, Colleen Nelson5,  
John Upham3, Hugh Reid7, Jamie Rossjohn7, Nicole La Gruta8, 
Ranjeny Thomas1, 6  
1 The University of Queensland Diamantina Institute, Translational 
Research Institute
2 Department of Rheumatology, Princess Alexandra Hospital
3 UQ School of Medicine Southern Clinical School
4 UQ-Mater Research Institute
5 Queensland University of Technology
6 Dendright Pty Ltd, Brisbane, QLD,
7 Monash University
8 University of Melbourne, Melbourne, VIC.
Rheumatoid Arthritis (RA) is an inflammatory autoimmune 
disease, causing significant social and economic burden.  The 
pathophysiological process begins years before RA diagnosis. 
At-risk subjects during the ‘pre-clinical’ phase carry HLA-DR 
risk genotypes, develop RA-associated autoantibodies, and 
are more likely to smoke. Although the mechanistic basis 
for smoking and RA development is unknown, the lung is 
an emerging site of pre-clinical immunoreactivity.  The pre-
clinical phase is opportune for research and prevention, 
including lifestyle and immunotherapy.  Therefore, we 
are recruiting first-degree relatives of RA patients into a 
prospective cohort with accompanying tissue biobank, 
to investigate genetic, environmental and immunological 
pathogenetic factors.  The program involves wide 
collaboration applying novel technologies for genotyping, 
microbiome analysis, enumeration, characterization and 
genomic analysis of antigen-specific cells and generation 
of humanized mice.  We will first compare immune and 
respiratory function in at-risk smokers and non-smokers as 
a novel approach to elucidate pathogenetic mechanism of 
smoking in RA development. 
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ENHANCING THE HOST ANTIMICROBIAL DEFENCE TO COMBAT 
CHALLENGING BACTERIAL INFECTIONS
Marcela Gatica-Andrades1, Tam T.K. Nguyen1, Orry Wyer1, 
Javier Melo Bolivar1, Ian H. Frazer1,2, Antje Blumenthal1,2
1  The University of Queensland Diamantina Institute, Translational 
Research Institute, Brisbane
2  Australian Infectious Diseases Research Centre, University of 
Queensland, Brisbane
Bacterial infections pose an important clinical challenge 
despite our extensive arsenal of antibiotics.  This is 
exemplified by lengthy treatments of chronic infections (e.g. 
tuberculosis), high mortality due to impaired immune control 
and excessive inflammation (e.g. Listeriosis, severe sepsis), 
and an alarming increase in antibiotic resistance. 
One attractive strategy for improved treatments for 
challenging infections is to enhance the endogenous 
anti-microbial defence.  We and others have associated 
the Wnt pathway with bacterial infections in patients and 
model systems implicating novel roles for this well-known 
developmental signalling pathway in immune responses 
to infections.  However, the nature of immune-related Wnt 
functions is largely unknown. Using in vivo infection models 
we show that Wnt pathway inhibition limits inflammation 
during infection with Listeria monocytogenes.  Moreover, 
inhibiting the Wnt pathway enhanced host control of Listeria 
likely due to more effective action of endogenous anti-
microbial defence mechanisms.  Novel drugs inhibiting the 
Wnt pathway are currently in clinical trials for cancer.  Thus, 
outcomes from this work have the potential to define novel 
ways to supplement treatments for infections that could be 
rapidly progressed towards practical application.
MODIFYING ADVANCED GLYCATION END PRODUCTS REDUCES 
EXPERIMENTAL TYPE 1 DIABETES
Danielle Borg
Mater Health Services
Type 1 diabetes (T1D) incidence within Australia has doubled 
within lower risk genotypes, a likely result of environmental 
risk factors.  We eat high levels of processed foods which 
contain advanced glycation end products (AgEs) an 
environmental trigger for islet autoimmunity in children. 
Our data suggests that if we lower the levels of AgEs we can 
reduce the levels of T1D diabetes in a time dependent fashion 
in T1D susceptible mice. Together with basic researchers 
based the University of Queensland, we aim to lower AgEs 
using a diet and a pharmaceutical drug during pregnancy or 
early in life and follow diabetes incidence in a T1D susceptible 
mouse model. 
Clinical research collaborations at Mater Health involved 
in the clinical study ENvironmental Determinants of Islet 
Autoimmunity (ENDIA), will validate our basic findings by 
examining dietary AgE intake in pregnant mothers and 
following the development of islet autoantibodies in their 
infants over three years.  This project will improve our 
understanding of AgE exposure on Type 1 Diabetes incidence 
and provide pre-clinical data for therapies that may prevent 
children from developing T1D in the future.
Monocytes Mediate and Determine the Cytoxic Responses to 
Anti-CD62L Therapy in Chronic Lymphocytic Leukaemia (CLL)
Melinda Burgess1,2, Nicholas Saunders1,Sally Mapp2, 
Catherine Cheung2, Lynne Chambers2, Louise Smith2,  
Nigel AJ McMillan3 Peter Mollee2, and Devinder Gill1,
1  University of Queensland Diamantina Institute, Brisbane, Australia
2 Department of Haematology, Princess Alexandra Hospital, Brisbane, 
Australia
3	 Griffith	Health	Institute	and	School	of	Medical	Sciences,	Griffith	
University, Southport, Queensland, Australia 
CLL is a B-cell malignancy characterised by defects in 
apoptosis. Previously, we have shown that CD62L (L-selectin) 
expression is increased in CLL cells in culture and that 
blocking CD62L induces significant cytotoxicity in CLL cells. 
During the course of these studies we found that PBMCs 
cultured from individual patients could be broadly classified 
as either sensitive to or insensitive to anti-CD62L-induced 
cytotoxicity and we sought to determine the mechanism 
of sensitivity and examine the importance of the CLL 
microenvironment in influencing anti-CD62L responses.  
The differential sensitivity to anti-CD62L therapy appears 
not be a direct action on CLL-B cells but mediated by the 
microenvironment and more specifically, mediated by 
monocyte-derived cells (MDC) from PBMCs. Furthermore, we 
were able to modify CD62L blockade responses from sensitive 
or insensitive samples simply by switching the MDCs. 
By understanding the mechanism involved in regulating 
sensitivity to CD62L blockade in patient CLL cells we will 
identify novel strategies to induce tumour cell death in CLL 
patients.
Research and Innovation Ideas
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INCREASING HEALTH PROFESSIONALS COMMUNICATION 
WITH PEOPLE WITH APHASIA: A PRE-POST INTERVENTION 
STUDY
Ashley Cameron1,2, Steven McPhail3,4, Kyla Brown5,3,  
Jennifer Fleming6,7, Jennifer Lethlean21,2, Emma Finch3
1 Division of Speech Pathology, School of Health and Rehabilitation 
Sciences, The University of Queensland, Brisbane, Australia 
2 Speech Pathology Department, Princess Alexandra Hospital, Brisbane, 
Australia 
3 Centre for Functioning and Health Research, Metro South Health 
Service District, Queensland Health, Brisbane, Australia 
4 School of Public Health & Social Work and Institute of Health and 
Biomedical Innovation, Queensland University of Technology, Brisbane, 
Australia
5 NHMRC Centre for Clinical Research Excellence Aphasia Rehabilitation, 
Brisbane, Australia
6 Division of Occupational Therapy, School of Health and Rehabilitation 
Sciences, The University of Queensland, Brisbane, Australia
7 Occupational Therapy Department, Princess Alexandra Hospital, 
Brisbane, Australia 
Background and aims:  People are often unaware of the 
cognitive and social competence of people with aphasia 
(PWA). As such, communication difficulties associated with 
aphasia can create significant barriers to the involvement 
of PWA in their medical management and rehabilitation. 
Communication difficulties associated with aphasia can 
be offset by supported conversation techniques employed 
health professionals (HPs). The aim of the present study is 
to investigate the effects of implementing a communication 
program with PWA and multidisciplinary HPs. 
Method:  A non-randomized trail (pre-post intervention 
study) of 52 multidisciplinary HPs was implemented. The 
program consisted of a pre-post questionnaire assessing the 
confidence and knowledge of HPs and a lecture / practical 
component utilizing information procured from Connect – 
Communication Disability Network. 
Results:  Higher confidence was reported post training mean 
(SD) 75.81 (12.16) than before training mean (SD) 46.56 
(15.71), t(51) = 12.479 (p <.001). Similarly, HPs also identified 
a greater number of supported conversation techniques 
(median 9, p < .001). 
Conclusion:  Preliminary evidence suggests training HPs 
in supported conversation may be an effective method to 
increase the confidence, knowledge and saliency of exchange 
for HPs when communicating with PWA. 
MASS SPECTROMETRY IDENTIFICATION AND VALIDATION OF 
SALIVARY PROTEIN BIOMARKERS OF HEART FAILURE
Michael Caragata1, Benjamin L. Schulz2, Justin Cooper-White3, 
John Atherton4, Karam Kostner5 and Chamindie Punyadeera*1 
1  University of Queensland Diamantina Institute, University of 
Queensland, Translational Research Institute, Woolloongabba, QLD 
4102, Australia
2  The School of Chemistry and Molecular Biosciences, University of 
Queensland, St Lucia, QLD Australia 
3 The Australian Institute for Bioengineering and Nanotechnology, 
University of Queensland, St Lucia, QLD, Australia. 
4 Department of Cardiology, Royal Brisbane Women’s Hospital, Brisbane, 
QLD, Australia 
5 Department of Cardiology, Mater Adult Hospital, Brisbane, QLD, 
Australia
Saliva has recently gained attention as a diagnostic fluid for 
detecting biomarkers in systemic diseases such as Heart 
Failure (HF) because it can be non-invasively collected. 
Therefore, we aimed to develop a robust method to detect 
biomarkers of HF in saliva, depleting the high abundant 
proteins and validating these markers using a mass 
spectrometry (MS) method called SWATH-MS.
Saliva samples were collected from controls (n=9) and HF 
patients (n=8). ProteoMiner® beads were used to deplete 
the high abundant proteins in saliva followed by trypsin 
digestion and information dependent acquisition LC-ESI-MS/
MS to identify proteins. Biomarkers were then validated with 
SWATH-MS. 
Validation using SWATH-MS identified a panel of four proteins 
which, when combined in a ratio abundance comparing 
controls to patients, display significant discrimination for HF 
patients over controls, ie Protein C:Protein D (p<0.0005, AUC= 
1, sensitivity 100%, specificity 88.89%), Protein B:Protein 
D (p< 0.0021, AUC= 0.9444, sensitivity 87.5%, specificity 
88.89%), Protein A:Protein D (p< 0.0015, AUC=0.9583 
sensitivity 87.5%, specificity 88.89%). These four salivary 
biomarkers should therefore be considered as a powerful 
biomarker panel for HF.
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A SALIVA BASED TEST FOR THE DETECTION OF HPV 
ASSOCIATED ORAL CANCERS
Ryan Chai1, Duncan Lambie2, Ian Frazer3 and  
Chamindie Punyadeera1
1 The University of Queensland Diamantina Institute, The University of 
Queensland, Translational Research Institute, Woolloongabba, QLD 
4102
2 The School of Medicine, the University of Queensland
3 Translational Research Institute
Human papilloma virus (HPV) infection is a major risk 
factor for a distinct subset of head and neck squamous cell 
carcinoma (HNSCC).  The incidence of HPV-associated HNSCC 
is increasing and there are no early detection methods 
with most cases at an advanced stage upon diagnosis.  The 
current study aims to develop a saliva-based assay for the 
detection of oncogenic HPVs in patients with oral squamous 
cell carcinoma (OSCC), recruited from the Head and Neck 
clinic at Princess Alexandra Hospital. Oncogenic HPV-16 
DNA was detected in the salivary rinse of 11/13 (84.6%) 
OSCC patients diagnosed with HPV-positive OSCC and none 
in the salivary rinse of patients with HPV-negative tumour 
(0/10).  In addition, HPV-related mRNA and protein are also 
being assessed in the salivary rinse to detect active and 
clinically relevant HPV infection.  The current study will aid 
in the detection of HPV infection in people at a high risk of 
developing HPV-associated HNSCC in a non-invasive and 
cost effective way. Early detection and intervention will 
significantly reduce the mortality and morbidity associated 
with HNSCC.
PROTEOGENOMIC CHARACTERISATION OF CIRCULATING 
ACUTE PHASE MARKERS AND BIOASSAY DEVELOPMENT IN 
SHEEP 
Saul Chemonges  
The University of Queensland & Queensland University of Technology 
Background: Relevant large animal models are essential 
in translational research.  Recent observations show that 
some sheep appear to be more susceptible to the effects 
of Escherichia coli lipopolysaccharide (LPS) endotoxin 
than others, despite having the same characteristics.  The 
reason behind this difference is unknown and has prompted 
studies aiming to explain the variation by proteogenomic 
characterisation of endotoxin-induced circulating acute 
phase biomarkers.  It is hypothesised that lifestyle, genetic 
trait, biochemical, immunological and inflammation marker 
patterns contribute in defining and predicting mammalian 
response to LPS.  
Methods:  Backgrounds of sheep enrolled in a primary study 
with an important translational focus that showed selective 
resistance to endotoxin were investigated.  Data on animal 
sources, production traits, management and preventive 
health practices were analysed.  
Results:  Endotoxin resistant sheep had been raised on open 
pasture and had a different vendor.  Susceptible sheep were 
from a government controlled scientific breeding colony with 
either wool or endoparasite resistance trait. 
Conclusion: Not all experimental sheep are the same.  
Proteogenomic study approaches may help to understand 
the mechanisms of selection to LPS morbidity in sheep and 
similar pathology in humans.  
A STREAMLINED ENGINEERING PLATFORM TO FABRICATE 
PATIENT-SPECIFIC IMPLANTS 
Mohit P. Chhaya, Prof Michael A. Schütz,  
Prof Dietmar W. Hutmacher
Queensland University of Technology
The concept of tissue engineering has long been hailed as 
the optimal solution to circumvent problems associated with 
organ failure.  The mechanical integrity of biodegradable 
implants for tissue engineering is controlled largely by its 
internal architecture. Looking at the literature, it is clear 
that there exists no optimisation in the design of these 
architectures. Such disregard in optimisations frequently 
lead to implant failures in animal models and is a primary 
concern for clinicians wishing to introduce tissue engineering 
scaffolds into the clinic. Our main value proposition is 
an engineering platform that allows researchers and 
clinicians to mix and match biocompatible implant design 
options, including material, dimensions, shape and 
internal architecture to create designs precisely optimised 
to the requirements of a specific patient and the planned 
reconstructive surgery.  We also plan to develop novel 
algorithms that would allow researchers to generate Finite 
Element models on any arbitrarily complex design of implants 
in order to computationally simulate mechanical loading 
and/or fluid flow.  Our technology will accelerate implant 
development, offer design freedom and effectively propel 
clinical scaffold-based tissue engineering from bench to 
bedside.  
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AN AUSTRALIAN NATIVE PLANT: A NOVEL ANTIMICROBIAL FOR 
THE TREATMENT OF MRSA. 
Hogan, RC1 and Collet, TA1
1 Indigenous Medicines Group, Tissue Repair and Regeneration Program, 
Cells and Tissue Domain, Institute of Health and Biomedical Innovation, 
Queensland University of Technology.
Introduction:  Contamination of a wound site with methicillin-
resistant Staphylococcus aureus (MRSA) is of major concern 
due to the resultant delay in wound healing.  Aboriginal 
herbal medicine has been used for thousands of years, 
hence, we selected an Australian native plant to evaluate its 
bactericidal activity against MRSA.
Methods:  The antimicrobial activity of plant A against MRSA 
was determined using the well and disc diffusion assays.  
Various concentrations (2.5-10ng) of crude plant extract 
were used for both methods (negative control=MilliQ water; 
positive control=Trimethoprim+Sulfamethoxasole).  
Results:  Plant A demonstrated significant bactericidal effects 
against MRSA using both methods.  At 24 hours, 5ng elicited 
the same zone of inhibition (10mm) against MRSA in the disc 
diffusion assay upon comparison to the positive control.  
Similar results were mirrored in the well diffusion assay 
(positive control=20mm; crude extract=15mm) at the same 
concentration.
Conclusion: This pilot study has demonstrated that crude 
extracts from plant A exhibit significant antimicrobial activity 
against MRSA.  Although preliminary, given the increasing 
incidence of antibiotic resistance coupled with the high 
prevalence of hospital-acquired MRSA infections, the benefits 
of such a novel antibiotic are substantial.  
‘WISH THEY COULD BE IN MY SHOES’: INNOVATIVE 
AMBULATORY CARE TRANSFORMATION NEEDED 
Jacqueline Cotugno
Princess Alexandra Hospital
Translation of innovative therapies in chronic disease 
management relies on constructive health professional 
and patient relationships to facilitate self-management.  
Perceived culture shifts that see people engaging as 
consumers of healthcare resources rather than patients of 
a didactic system, requires review of current ambulatory 
service delivery.  The aim of this study was to assess patient 
perceptions of the disease management journey and gain 
insight from their experiences to identify barriers to research 
translation.  Discovery interviews were independently 
conducted with patients from the PAH diabetes outpatients. 
These patient accounts challenge our current management 
approach and highlight a disconnect between consumers 
and the healthcare system; ‘I don’t know if they really fully 
understand what [a] struggle it is’, ‘what gets me down more, 
the fact that, well who are we seeing today’, ‘sometimes 
we walk out and say that was a waste of time’ ‘they tried 
to explain this and it went over my head’.  These patient 
interviews demonstrate an innovative transformation of 
chronic disease ambulatory care is needed to better engage 
consumers and ultimately improve health outcomes 
A BETTER TEST FOR SPECIFIC IMMUNODIAGNOSIS OF 
SUBTROPICAL BAHIA GRASS POLLEN ALLERGY
Victoria L Timbrell1, Lindsay Riebelt2, Claire Simmonds2, 
 John W Upham1, Peter Smith3, Sheryl van Nunen4,  
William Smith5, Andrew Mclean-Tooke6, Graham Solley7,  
Anita Kober8, Daman Langguth2, Janet M Davies1 
1 The University of Queensland, Brisbane, Australia
2  Sullivan Nicolaides Pathology, Brisbane, Australia
3 Queensland Allergy Services, Goldcoast, Australia
4 Royal North Shore Hospital and Sydney Medical School-
University of Sydney, Sydney, Australia
5 Royal Adelaide Hospital, Adelaide, Australia
6 Freemantle Hospital, Sir Charles Gairdner Hospital, Nedlands, 
Australia
7 Watkins Medical Centre, Brisbane, Australia
8 ThermoScientific,	Uppsala,	Sweden	
Background: grass pollen is a major global cause of hayfever 
contributing to the financial and medical burden of allergic 
asthma. A standardised assay for Bahia grass (Paspalum 
notatum) pollen (BagP) is needed for better immunodiagnosis 
of subtropical grass pollen allergy. 
Methods: A high throughput test based on serum IgE to the 
major allergen Pas n 1 (patented in Australia, continuing in 
USA) purified from BaGP was established on the ImmunoCAP 
platform (Thermofisher, Sweden) and validated by Sulivan 
Nicolaides Pathology (Taringa) with 316 subjects recruited 
with ethical approval. 
Results: The test performance and reproducibility were 
outstanding. Pas n 1 IgE was highly correlated with current 
tests based on crude whole pollen extracts; BagP skin 
prick test (r = 0.775, p <0.0001) and BagP IgE (r = 0.891, p < 
0.0001). The diagnostic sensitivity (91.8%) and specificity 
(92.6%) were excellent (ROC area 0.954, p < 0.0001). 
Conclusions: This molecular component immunoassay for 
Pas n 1 IgE has potential to improve the diagnosis of patients 
with grass pollen allergy in subtropical regions with clinical 
relevance for large markets including parts of Australia, India 
and southern USA. 
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FLUOROURACIL TOXICITY: EVIDENCE THAT A TRANSPORT 
DEFECT EXPLAINS THE MAJORITY OF CASES
John A Duley1,2, Ming Ni1, Gareth Price2, Bruce G Charles1, 
Ross LG Norris1,2,3, Marion Harris4, Les J Sheffield5,  
Andre BP van Kuilenburg6, Catherine Shannon2
1 School of Pharmacy, UQ, QLD
2 Mater Research Institute, TRI, QLD
3 St Vincents Hospital, Sydney, NSW
4 Monash Medical Centre, Melbourne, VIC
5 GenesFX Health, Melbourne, VIC
6 Laboratory of Genetic & Metabolic Diseases, Academic Medical Centre, 
Amsterdam, The Netherlands
Introduction: About 1/3 of severe side effects during cancer 
chemotherapy with 5-fluoro-uracil (5FU) or capecitabine 
results from partially deficient dihydropyrimidine 
dehydrogenase (DPD), the major rate-limiting step for 5FU 
catabolism. But the underlying cause of the remaining 2/3 of 
toxicity has remained unknown. 
Aim: To develop a test to predict 5FU or capecitabine toxicity.
Methods: Twelve healthy male adults, and six patients 
who had experienced severe 5FU or capecitabine toxicity, 
were given 250 mg thymine (5-methyl-uracil) orally. Timed 
plasma, urine and saliva samples were collected, and 
analysed by HPLC-tandem mass spectrometry for thymine 
and its successive catabolites dihydrothymine and 
ureidoisobutyrate. 
Results: Thymine was quickly absorbed into plasma by all 
subjects, mean Cmax= 170 (range 34-679) ug/L, and the 
estimated clearance (Cl/F) had a broad range in excess of liver 
blood flow (mean 57.9, range 9.30-175 L/h/kg). Interestingly, 
basal plasma dihydrothymine was ~9-fold higher than 
thymine. Dihydrothymine and ureidoisobutyrate exhibited 
formation-rate limited kinetics. In two of the patients, delayed 
thymine clearance was consistent with DPD-deficiency, 
confirmed genetically. However, three other patients 
exhibited rapid thymine uptake and grossly raised plasma 
Cmax values, 30-fold above the control average (mean 4190, 
range 3000-6190 ug/L).
Discussion:  The thymine load test easily distinguished DPD 
deficiency from control DPD. A hitherto undescribed ‘rapid 
thymine uptake’ pharmacokinetic phenotype was discovered 
in three of six patients. We propose this abnormal phenotype 
is polymorphic among humans, underlying the majority of 5FU 
and capecitabine toxicity cases.
This project won an NHMRC ‘Best of Ten’’ award for 2013.
USING OLD DRUGS TO TARGET NEW PATHWAYS IN 
OSTEOSARCOMA METASTASIS
Topkas, E1, Cai, N1, Cumming, A1, Joubert, W2, Sommerville, 
S2,3, Straw, R4, Bennett, T4, Thompson, M5, O’Connell, K5, 
Cooper, M6, Brockley, L6, Peaston, A7, Wyatt, K8, Saunders 
NA1, Endo-Munoz, L1
1 The University of Queensland Diamantina Institute
2 Princess Alexandra Hospital
3 The Wesley Hospital
4 Brisbane Veterinary Specialist Centre
5 Veterinary Specialist Services, Brisbane
6 Victorian Animal Cancer Care, Melbourne
7 The University of Adelaide School of Animal and Veterinary Sciences
8 Perth Veterinary Specialists
Osteosarcoma (OS) is the most common primary bone 
tumour in children and adolescents. In spite of aggressive, 
multiagent chemotherapy, the 5-year survival of patients who 
develop metastatic disease is less than 20%. Pulmonary 
metastasis thus remains the most significant and untreatable 
complication of OS. The development of more effective 
targeted therapies is therefore vital. 
To identify potential therapeutic targets for OS metastasis, 
we employed a multi-omics approach to interrogate highly- 
and poorly-metastatic clonal variants of OS. We found 
high expression of thioredoxin reductase (TrxR) associated 
with a highly metastatic phenotype of human OS . We then 
confirmed that TrxR was selectively overexpressed in 1/3 
of biopsies taken from patients who developed pulmonary 
metastases.  
Auranofin is a selective inhibitor of TrxR.  Auranofin, is an 
old drug clinically used for the treatment of inflammatory 
arthritis. Most notably, treatment with auranofin significantly 
(P = 0.0081) reduced lung metastasis in an orthotopic mouse 
model of OS.
Our work opens the possibility that TrxR inhibitors, already 
approved for clinical use, have the potential to become the 
first selective antimetastatic therapy for OS. A nationwide 
clinical trial of auranofin for canine OS is in progress.  
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SYNTHETIC LETHAL SCREEN IDENTIFIES AURORA A AS A 
SELECTIVE TARGET IN HPV DRIVEN CERVICAL CANCER
Fawzi Faisal, A. Bokhari, Max Ranall, Weili Wang, Alex 
Stevenson, Sara McKee, Graham Leggatt, Melanie Murell1, 
Daniel Clarke1, Madison Kelly1, Brooke Marfell2, Tom Gonda3, 
Nigel McMillan1, Brian Gabrielli
1 The University of Queensland Diamantina Institute, Translational 
Research Institute, Brisbane Queensland
2	 Griffith	Health	Institute,	School	of	Medical	Science,	Griffith	University,	
Gold Coast
3 Mater Research, Translational Research Institute, Brisbane Queensland. 
School of Pharmacy, The University of Queensland, Brisbane, 
Queensland.  
Cancers caused by HPV are responsible for over 610,000 
deaths annually and represent 5% of the total cancer burden 
worldwide.  HPV oncogenes disable a number of tumour 
suppressor pathways, but may also provide an opportunity 
to selectively target the destruction of HPV-transformed 
cells.  We have performed an siRNA kinome screen to identify 
genes that when depleted are synthetically lethal with HPV 
transformation.  The primary and validations screens have 
confirmed Aurora A kinase (AURKA) as a potential synthetic 
lethal target selective for HPV transformed cells.  We found 
that MLN8237, selective small molecule AURKA inhibitor, 
selectively promoted apoptosis in the HPV cancers.  The drug 
was shown to target the HPVE7 oncogene, and the apoptosis 
was sensitive to Mcl-1 but not Bcl-2 over expression.  
Xenograft experiments with cervical cancer cell lines showed 
MLN8237 completed inhibited growth of HPV but not non-
HPV xenografts during treatment.  A second transgenic model 
of premalignant disease driven solely by HPVE7 similarly 
demonstrated sensitivity to drug treatment.  These findings 
provide strong evidence that MLN8237 represent a potent 
therapeutic against HPV driven cancers.
THE WNT PATHWAY IN SEPSIS – POTENTIAL FOR NEW 
BIOMARKERS AND ADJUNCT THERAPEUTICS?  
Marcela Gatica-Andrades1, Jeremy Cohen2,3, Jessica Kling1, 
Alicia Kang1, Tam T.K. Nguyen1, Li Zhang4, Mark Morrison1, 
Bala Venkatesh5,3, Antje Blumenthal1,6
1  The University of Queensland Diamantina Institute, Translational 
Research Institute, Brisbane
2  Department of Intensive Care Medicine, Royal Brisbane and Women’s 
Hospital
3  The University of Queensland, School of Medicine, Brisbane
4		Centre	for	Health	Practice	Innovation,	Griffith	Health	Institute,	Griffith	
University, Brisbane
5  Department of Intensive Care Medicine, Princess Alexandra Hospital, 
Brisbane
6  Australian Infectious Diseases Research Centre, University of 
Queensland, Brisbane
Sepsis is a common and increasing cause of major morbidity 
and mortality in Australia, and around the world.  There 
is an urgent need for new adjunctive treatment options. 
Dysregulated immune responses commonly observed in 
septic patients have been a major target for clinical trials 
over the last 20 years.  Yet, targeting immune parameters in 
isolation has not led to any successful outcomes. 
Identification of new intervention strategies in septic patients 
likely requires consideration of host factors that are not 
traditionally associated with immune responses to infection. 
We observed elevated expression of Wnt ligands, activators 
of a cell signalling network best known for its functions in 
embryonic development, in the peripheral blood of septic 
shock patients and in vivo models of sepsis. 
Pharmacological interference with Wnt pathway activity in 
animal models of systemic bacterial challenge dampened 
potentially harmful inflammation while preserving pathogen 
control. Our observations warrant assessment of Wnt 
expression as new biomarkers that may enable stratification 
of septic patients and the potential for Wnt pathway inhibitors 
as adjunct therapeutics in sepsis.
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UTILISATION OF NICOTINE REPLACEMENT THERAPY WITH A 
HOSPITAL PHARMACIST INITIATED SMOKING-CESSATION 
INTERVENTION
Gupta D1, Upham J2, Winckel K3, Burrows J4, Ross J5,  
Saywell D6
1 Pharmacist, Princess Alexandra Hospital, Brisbane
2 Respiratory Consultant, Princess Alexandra Hospital, Brisbane
3 Senior Pharmacist, Princess Alexandra Hospital, Brisbane
4 Program Coordinator, School of Pharmacy, University of Queensland, 
Brisbane
5 Respiratory Nurse Consultant, Princess Alexandra Hospital, Brisbane
6 Assistant Director of Pharmacy, Princess Alexandra Hospital, Brisbane
Nicotine replacement therapy (NRT) significantly increases 
the chance of stopping smoking. Hospitalisation provides an 
opportunity to discuss smoking-cessation and initiate NRT in 
current smokers. 
However, a 2012 Drug Use Evaluation of NRT in inpatients at 
PAH showed poor prescription rates of NRT, 14/44 (32%) in 
inpatients and 3/34 (9%) patients on discharge. 
A Randomised Controlled Trial in 2013 evaluated the 
utilisation of hospital-pharmacist initiated NRT. Results 
showed significantly higher rates of NRT uptake in inpatients 
in the intervention arm 41/50 (82%) vs. 12/50 (24%) (p<0.001, 
chi square) in the control arm. 
At discharge, 34/50 (68%) patients in the intervention arm 
had NRT prescribed vs. 6/50 (12%) (p<0.001, chi square) in 
the control arm.
As a result, a “Pharmacist Initiation of NRT” protocol was 
recently approved at PAH, to enable ward pharmacist 
involvement in the management of acute nicotine withdrawal, 
and facilitation of ongoing NRT supply on discharge. 
Whilst enhancing NRT use is one step towards smoking-
cessation, exploring options for a co-ordinated/
multidisciplinary approach with ongoing follow-up in the 
community is required to assess the potential benefits in 
terms of long term abstinence.
DEFINING THE MODE OF TUMOUR HETEROGENEITY BY REAL-
TIME CELL CYCLE IMAGING
Nikolas K. Haass
Translational Research Institute
Solid cancers are composed of heterogeneous zones 
containing actively cycling and quiescent cells. Despite 
considerable insight into the molecular mechanisms 
underlying aberrant cell cycle progression, there is limited 
understanding as to what regulates the positioning of 
proliferating or quiescent cancer cells within the tumor 
microenvironment, and what impact the cell cycle status has 
on melanoma cell invasion or drug sensitivity.  Utilizing the 
fluorescent ubiquitination-based cell cycle indicator (FUCCI) 
to longitudinally monitor proliferation and migration of 
melanoma cells in vitro and in vivo, we found that invading 
melanoma cells cycled actively, while g1-arrested cells 
showed decreased invasion. Notably, melanoma cells in a 
hypoxic environment or treated with MAPK pathway inhibitors 
remained reversibly g1-arrested for extended periods of time.  
Our data challenge the idea that the invasive and proliferative 
capacity of melanoma cells are mutually exclusive, and 
further demonstrate that a reversibly g1-arrested sub-
population survives in the presence of targeted therapies.  
Consequently we propose that more efficient targeting 
of these quiescent melanoma cell sub-populations will 
contribute to decreasing the likelihood of recurrence. 
TARGETING THE CELL SURFACE PROTEIN CDCP1 IN A MODEL 
OF OVARIAN CANCER
Brittney Harrington1, C. Davies2, S.Wallace2, Y. He1,  
J.E .Armes2, L.C. Perrin3, J.D. Hooper 1
1 Mater Research Institute, Translational Research Institute, Brisbane, 
Queensland, Australia
2 Mater Pathology, The Mater Misericordiae Hospital, South Brisbane, 
Queensland, Australia
3 Centre for Gynaecological Cancer, The Mater Misericordiae Hospital, 
South Brisbane, Queensland, Australia
Epithelial ovarian cancers are heterogeneous carcinoma. High 
grade serous ovarian cancer (HgSC) is the most commonly 
represented histotype accounting for 70% of all cases.  The 
5 year survival rate remains poor as most patients present 
with advanced disease which presents a challenge for 
treatment.  Furthermore, many promising targeted therapies 
perform poorly in clinical trials.  Conventional cell-line derived 
mouse tumour models have been useful but an ovarian 
cancer model that reflects the heterogeneity of this disease 
is needed.  To test whether targeting the cell surface protein 
CUB domain-containing protein 1 (CDCP1) is appropriate 
in HgSC, a patient derived xenograft model (PDX) was 
developed.  CDCP1 has been shown to promote metastasis 
in cancer models and is associated with a poor prognosis in 
some cancers.  Analysis of HgSC tissue revealed that CDCP1 
was over-expressed in 74% of tumours.  CDCP1 targeting in 
HGSC cell lines significantly reduced tumour burden in vivo.  
Most excitingly, tumour burden was significantly reduced in 
a PDX of HgSC treated with anti-CDCP1 antibody.  These data 
show that CDCP1 warrants further investigation as a potential 
therapeutic target. 
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EXPLORATORY STUDY OF ARM TRAINING +TRNS IN STROKE 
SURVIVORS WITH SEVERE PARESIS.
Kathryn S Hayward1, Richard G Carson2,3, Sandra G Brauer1, 
Kathy Ruddy4
1  Division of Physiotherapy, School of Health and Rehabilitation 
Sciences, The University of Queensland, Brisbane, Australia
2  School of Psychology, Queen’s University, Belfast, United Kingdom
3  School of Psychology & Trinity College Institute of Neuroscience, Trinity 
College, Dublin, Ireland
4  Department of Health Sciences and Technology, Eidgenössische 
Technische	Hochschule	Zurich,	Zurich,	Switzerland
Stroke survivors with severe arm paresis have the poorest 
functional prognosis. There is accumulating evidence of the 
individual benefit of task-oriented training and non-invasive 
brain stimulation (NIBS) techniques, such as transcranial-
random noise stimulation (tRNS). However, investigation of 
the combined effect in stroke is unknown. 
Thus, our aim is to undertake a pilot triple-blind RCT to 
investigate the therapeutic and neuroplastic effect of 
combining voluntary motor timed tRNS with task-oriented 
training in stroke survivors with chronic and severe paresis. 
Ten stroke survivors will be randomly allocated to 12-sessions 
of task-oriented training with t-RNS or sham-tRNS. 
Therapeutic effects will be evaluated using clinical measures 
of arm recovery, and neuroplastic effects through structural 
and functional neuroimaging. 
This innovative research has the potential to extend positive 
functional outcomes for stroke survivors with severe paresis 
beyond those currently realised. The use of voluntary motor 
drive to trigger delivery of NIBS and the combination of 
structural and functional neuroimaging in a population of 
chronic and severe stroke survivors are novel. 
This project partners UQ with Queens University Belfast, 
Trinity College Dublin and Eidgenössische Technische 
Hochschule Zurich.
RISK STRATIFICATION OF OLDER PEOPLE USING A FRAILTY 
INDEX 
Ruth E. Hubbard, Consultant Geriatrician
Princess Alexandra Hospital 
Introduction: In this prospective cohort study, 1418 patients 
(mean 81.0y) were assessed at admission using the interRAI 
Acute Care (AC) instrument. The instrument screens a large 
number of domains, which were coded as deficits. These were 
summed and divided by the total number considered (here, 
56) to yield a Frailty Index with theoretical range 0-1. Higher 
values indicate greater frailty.
Results: Patients discharged to the community (n=931) 
were the least frail (0.28 ± 0.12), while those discharged to 
rehabilitation (n=209), residential aged care (n=206) or who 
died (n=57) were progressively frailer (0.38 ± 0.13; 0.41 ± 0.14; 
0.46 ± 0.17 respectively). After adjusting for age and gender, 
an increase of 0.1 in FI was associated with a 47% increased 
likelihood of being discharged to a higher level of care (OR: 
1.47; 95% CIs 1.33-1.62). A higher FI was also significantly 
correlated with increased length of stay.
Potential Outcomes: Integration of frailty quantification 
into an existing assessment system, which serves other 
clinical and administrative purposes, could facilitate the risk 
stratification of older inpatients and help target care more 
appropriately.
WHEN IS NEGATIVE POSITIVE: CLINICAL SIGNIFICANCE FOR 
RHD VARIANTS IN PREGNANCY MANAGEMENT
Dr Catherine Hyland 
Princess Alexandra Hospital
Haemolytic disease of the fetus and newborn (HDFN) was 
once a major cause of infant morbidity and mortality and 
is now successfully managed by anti-D immunoglobulin 
prophylaxis for RhD-negative women.  However, a small 
number of women still become alloimmunised.  
For these high risk pregnancies we established and 
translated, with NATA accreditation, a non-invasive prenatal 
test for fetal RHD genotyping of cell-free fetal DNA in the 
maternal circulation. The test requires that the serologically 
RhD-negative mother is genotypically RHD negative. However, 
maternal genetic D variants hinder this fetal genotyping.  Our 
studies revealed 12 RHD variants, one novel, amongst 770 
pregnancies in D-negative women.   
A collaborative study between Mater Health Services, Royal 
Brisbane Hospital, the Chinese University of Hong Kong and 
the Blood Service, using digital PCR technology, defined 
the clinical significance for one RHD variant illustrating the 
applicability of this technology. 
Further studies of D variants at the Blood Service have 
revealed six novel genes. Application of digital PCR 
technology and other nucleic acid technologies have shown 
the need for leading edge genetic technologies to diagnose 
HDFN in these pregnancies. 
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THROMBOSPONDIN-1 – A POTENTIAL GLUCOCORTICOID 
BIOMARKER
Warrick Inder, Johanna Barclay, Christopher Sadler,  
Christina Jang, John Prins, Jon Whitehead
Princess Alexandra Hospital
glucocorticoids are steroid hormones similar to the naturally 
occurring adrenal hormone cortisol. In physiological doses, 
glucocorticoids are used to replace cortisol deficiency and 
in high dose to treat a wide range of inflammatory and 
malignant conditions. However, even subtle excess may 
cause adverse effects, and recent literature highlights an 
association between glucocorticoid dose and increased 
mortality. Currently there is no established biomarker of 
glucocorticoid action which might enable the fine tuning 
of glucocorticoid dose in an individual. Such a biomarker 
would need to demonstrate a glucocorticoid dose-dependent 
change in concentration and ideally itself be correlated with 
adverse outcome. 
Thrombospondin-1 (THBS1) is a matricellular protein, widely 
expressed in a range of tissues and measurable in human 
plasma. Earlier studies have indicated that THBS1 is strongly 
induced by glucocorticoids in vitro. Our research will examine 
the response of THBS1 to changes in glucocorticoid levels in 
human volunteers. The identification of a readily measurable 
biomarker would revolutionise the way glucocorticoid therapy 
is monitored, and would be a shining example of translational 
research having a direct beneficial outcome in the clinical 
setting.
NEXT GENERATION SEQUENCING FOR MATURITY ONSET 
DIABETES OF THE YOUNG
Stephanie R. Johnson1,2,3,  Louise Conwell3,4, Mark Harris1,3, 
Emma L. Duncan1,3,5
1 The University of Queensland Diamantina Institute, Translational 
Research Institute, Brisbane, Australia
2 Department of Endocrinology, Mater Children’s Hospital, Brisbane, 
Australia
3 School of Medicine, The University of Queensland, Brisbane, Australia
4 Department of Endocrinology, Royal Children’s Hospital, Brisbane, 
Australia
5 Department of Endocrinology, Royal Brisbane and Women’s Hospital, 
Brisbane, Australia
Maturity-onset diabetes of the young (MODY) is a monogenic 
form of diabetes, caused by mutations in any of thirteen 
known genes.  Traditionally, diagnosis requires Sanger 
sequencing each gene individually.  In contrast, massive 
parallel sequencing enables sequencing of multiple genes 
simultaneously.  We assessed whether whole exome 
sequencing (WES) was sensitive and specific for mutation 
detection in MODY. 
WES was undertaken in five subjects with known mutations 
and eleven subjects clinically diagnosed with MODY but no 
previously identified mutation.
Three of five known mutations were detected by WES using 
our standard in-house bioinformatics analysis, with no false 
positives.  A large deletion encompassing HNF1B (MODY 
5) was subsequently detected using Exomedepth.  The 
fifth mutation (in INS) was not detected due to insufficient 
coverage despite prediction of complete INS capture by 
the Nimblegen platform; this sample is re-running with an 
alternative platform. Two of the unknown samples had novel 
mutations in known MODY genes, ABCC8 and HNF4A.  
WES can identify the genetic mutations of MODY. However, 
both laboratory and bio-informatics approaches need to 
be considered carefully a priori for maximum sensitivity of 
mutation detection. 
CAN DEEP BRAIN STIMULATION BE APPLIED TO PSYCHIATRIC 
DISORDERS? A SYSTEMATIC REVIEW AND META-ANALYSIS
S. Kisely1,2,3, K. Hall 1, D. Siskind1,2,3, J. Frater 2, S. Olsen 2,3, D. 
Crompton 2,3
1 School of Medicine, The University of Queensland, Qld, Australia
2 Princess Alexandria Hospital, Woolloongabba, Qld, Australia
3  Centre for Neuroscience, Recovery and Mental Health, Diamantina 
Health Partners Qld, Australia
Background: Deep brain stimulation is increasingly being 
applied to psychiatric disorders. Double-blind, randomised 
controlled trials (RCTs) of active versus sham treatment have 
been limited to small numbers.
Objectives:  We undertook a systematic review and meta-
analysis of DBS effectiveness for psychiatric disorders 
Method: We search for double-blind, RCTs of active versus 
sham treatment using PubMed/Medline and EMBASE up till 
April 2013.  We assessed differences in final values between 
the active and sham treatments for parallel-group studies and 
paired analyses in changes from baseline score for cross-over 
designs.
Results: We included five studies, all of obsessive-compulsive 
disorder. 44 subjects provided data for the meta-analysis. 
The main outcome was a reduction Yale–Brown Obsessive 
Compulsive Scale scores. Patients on active, as opposed to 
sham, treatment had a significantly lower mean score (MD 
–8.93; 95%CI, -13.35 to –5.76; P<0.001), representing partial 
remission.  There were also significant differences between 
active and sham treatments for two studies using the 
Hamilton Depression Rating Scale (MD –7.89; 95%CI, -13.86 
to –1.91; P=0.01).  However, a third experienced significant 
adverse effects (n=16).  
Conclusions: DBS shows promise for treatment-resistant OCD. 
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IDENTIFICATION OF CANDIDATE FUNCTIONAL SHORT TANDEM 
REPEATS FOR PROSTATE CANCER CASE-CONTROL STUDIES.
John Lai1,2,3, Jiyuan An1,2,3, Colleen C Nelson1,2,3, Zsofia Kote-
Jarai4, Douglas Easton5, Ali Amin5, Rosalind A. Eeles4 on 
behalf of PRACTICAL consortium, Judith A Clements1,2,3, 
Jyotsna Batra1,2,3
1 Australian Prostate Cancer Research Center-Queensland
2 Queensland University of Technology, Institute of Health and 
Biomedical Innovation
3 Translational Research Institute, 37 Kent St, Woolloongabba, QLD
4 The Institute of Cancer Research, London, United Kingdom
5 The Royal Marsden NHS Foundation Trust, London and Surrey, UK SM2 
5NG
Introduction: SNPs account for only ~30% of heritable 
prostate cancers (PCas). Thus, we assessed for other 
polymorphism such as short tandem repeats (STRs) that 
might account for some of the missing PCa heritability.
Methodology: Potential polymorphic functional STRs were 
identified by analysing ChIPseq and RNAseq data from 
PCa cells treated with androgens or anti-androgens, and 
genotyping was carried out using RT-qPCR. 
Results: For the RNAseq analysis, most expressed STRs 
occurred in genes that are down-regulated by androgens or 
anti-androgens. Some of these STRs were located in genes 
which are over/under expressed in PCas compared to their 
corresponding normal prostate cells in clinical datasets. 
Our ChIPseq analysis indicates that STRs are located within 
androgen receptor and RNA polymerase II bound DNA, or 
within histone (H3K4me3, H3K9me3, H3K27me3) occupied 
regions. Importantly, we show that some of these STRs are 
polymorphic.
Potential outcome: We propose that our candidate 
polymorphic STRs should be prioritised for future large scale 
case-control association studies. We propose that STRs are 
functional elements of the PCa phenotype, and may account 
for some of the missing PCa heritability.    
A NEW WAY TO SCREEN HEAD AND NECK SQUAMOUS CELL 
CARCINOMA
Yenkai LIM1, Yunxia WAN1, William B. COMAN2, Chris PERRY3 
and Chamindie PUNYADEERA1*
1 University of Queensland Diamantina Institute, Translational Research 
Institute, Brisbane, QLD
2 University of Queensland, School of Medicine, Herston, QLD 
3 Department of Otolaryngology, Princess Alexandra Hospital, 
Woolloongabba, QLD
Head and neck squamous cell carcinoma (HNSCC) is a 
heterogeneous group of tumours with a 5 year survival rate 
of <40%. Risk factors for HNSCC include smoking, alcohol 
consumption and human papillomavirus (HPV) infections. 
DNA methylation in tumour suppressor genes occur at an 
early stage of tumorigenicity. As such, DNA methylation can 
be used as an early diagnostic biomarker. Saliva is an ideal 
diagnostic medium to determine head and neck cancer 
events due to its proximity to the tumours. 
Methods: We have investigated the methylation profiles 
of tumour suppressor genes (RASSF1β, DAPK1, TIMP3, APC, 
PCQAP/Med 5, p16 and p15) in saliva from healthy controls 
(n=30), healthy smokers (n=20) and HNSCC patients (n=30). 
We used methylation-specific polymerase chain reaction.
Results: DNA hypermethylation was observed in saliva 
collected from HNSCC patients compared to healthy controls; 
RASSF1α (p<0.05), APC (p<0.001), p16 (p<0.001), PCQAP 
(p<0.001) and TIMP3 (p<0.001). 
Salivary DNA methylation was increased in healthy smokers 
for TIMP3 and p16 (p<0.01 and p<0.05 respectively) compared 
to healthy controls.
Salivary DNA methylation of TIMP3 and p16 are potential 
screening targets for HNSCC.
PREDICTING PROSTATE TUMOR METASTASIS WITH A NOVEL 
TIE-2 ISOFORM
Patrick Ling
Queensland University of Technology
Bone metastasis occurs in more than 80% of advanced 
prostate cancer (PCa) cases, and is the major cause of 
morbidity and mortality in PCa patients. Ample evidence 
supports the idea that tumor metastasis originates from a 
rare population of cancer cells known as cancer stem cells 
(CSCs).Unfortunately, little is known about the identity of 
these cells, making it difficult to detect or target prostate 
tumor metastasis.  Here we reported the identification of 
Tie-2P (Tie-2-prostate specific), a novel isoform of the Tie-
2 tyrosine kinase receptor required for the bone marrow 
homing and colonization of hematopoietic stem cells. We 
found that Tie-2P expresses exclusively in a rare population 
of prostate cancer cells that are capable of metastasizing to 
the bone.  Meanwhile, expression of the Tie-2P was found to 
associate with resistance of the prostate cancer cells toward 
chemotherapeutic drug.  Our data suggest that Tie-2P could 
be developed as a prognostic marker for the detection of 
early dissemination of prostate cancer cells into the bone.  
This warrants further validation with prostate cancer samples 
available in the Urology Department of the PA hospital. 
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NORMOTHERMIC MACHINE PERFUSION OF HUMAN DONOR 
LIVERS
David Lockwood, Janske Reiling, Kim Bridle, Cate Campbell, 
Jonathan Fawcett
Princess Alexandra Hospital
There is a shortage of donor livers for human transplantation. 
Some potential donor livers are discarded because current 
selection criteria identify them as being at high risk for not 
working e.g. because of excessive fat in the liver. However, 
some of these organs might actually function satisfactorily. 
We have developed a system for perfusing human donor 
livers using a modified cardiac bypass machine.  This 
system therefore allows us to study the performance of 
these currently unusable livers, for 6 hours or more. We have 
demonstrated that the system allows the donor liver to clear 
lactate, synthesise urea and produce bile.  
We can also take biopsies to analyse any underlying liver 
disease or damage that the liver has sustained during 
retrieval which might compromise function.  Using this 
system we predict that it will be possible to evaluate whether 
some currently unusable donor livers could safely be used 
for clinical transplantation thereby offering the possibility of 
transplanting more Queensland patients.
DEVELOPMENT AND VALIDATION OF INSTRUMENT TO ASSESS 
CARDIAC RISK DURING CHEMOTHERAPY 
Alexandra McCarthy
Chair of Cancer Nursing, Princess Alexandra Hospital 
Cardiotoxicity can be a devastating outcome of breast cancer 
therapy. Accurate and timely assessment of cardiac risk 
before treatment can modify this risk1,6-11. However, there 
is currently no robust risk assessment tool to enable such 
assessments12,13. In addition, the prevalence of cardiac risk 
factors in this population is not known12,13.
The aims of this study are to:
1. Develop and validate a cardiotoxicity risk assessment 
tool that enables stratification of breast cancer patients 
considered for cardiotoxic therapy to appropriate clinical 
intervention. The tool will capture the following domains:
a. Cardiac risk factor assessment and Absolute Risk 
calculation
b. Cancer-specific and cancer treatment-related cardiac 
risk
c. Social determinants of cardiac health 
d. Patient-reported knowledge, attitude, behaviour, 
willingness and ability to modify lifestyle and reduce 
cardiac risk factors
5. Determine the prevalence of risk factors associated with 
cardiotoxicity in a large sample of breast cancer patients.
The outcomes of this study will be the development of a 
validated cardiac risk assessment instrument ready for 
translation to practice, and determination of the prevalence 
of cardiac risk in women treated for breast cancer. 
WHOLE EXOME SEQUENCING IN GENETIC CONDITIONS 
CAUSED BY LARGE AND/OR MULTIPLE GENES
Aideen McInerney-Leo1, Mhairi Marshall1, Paul Leo1, Jessica 
Harris1, Brooke Gardiner1, Matt A. Brown1 and Emma L. 
Duncan1,2
1 University of Queensland Diamantina Institute 
2 Royal Brisbane and Women’s Hospital
Whole exome sequencing (WES) is not commonly used for 
genetic testing. Instead, most laboratories use targeted 
candidate gene capture.  However, targeted capture platforms 
are expensive and cannot incorporate new genes.  We 
evaluated the performance of WES in individuals with Marfan 
syndrome (MFS) or osteogenesis imperfecta (OI) – arising 
from mutations in three large genes; phaeochromocytomas 
(PCC) and paragangliomas (PgL) - mutations by numerous 
genes; and short rib polydactyly syndromes (SRP), associated 
with mutations in both large and numerous genes.
WES was performed using Illumina TruSeq and Roche 
Nimblegen capture technologies on an Illumina HiSeq2000 
platform.  The MFS/OI/PCC/PgL samples were tested 
previously and were analysed blindly.  WES accurately 
identified mutations in 13/13 OI cases; 9/10 MFS cases and 
11/11 PCC/PgL patients.  In SRP, mutations were detected in 
known genes in 11 of 13 cases.  
One further case had a single deleterious mutation in WDR60 
but a second mutation was not identified. A new candidate 
gene was identified in the final case.  WES is a sensitive, 
efficient, cost-effective and rapid means of sequencing 
multiple genes and simultaneously allows for new gene 
discoveries.
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TARGETING DRUG INDUCED CANCER STEMNESS TO PREVENT 
ACQUIRED DRUG RESISTANCE
Dinoop Ravindran Menon1,2, Suman Das2, Silvia Schauer2, 
Gao Zhang3, Gerald Hoefler2, Meenhard Herlyn3, Peter Soyer1, 
Brian Gabrielli4, Helmut Schaider1
1  Dermatology Research Centre, Translational Research Institute, School 
of Medicine, The University of Queensland, Woolloongabba, 4102 
Queensland, Australia
2		Medical	University	of	Graz,	Auenbruggerplatz	8,	8036	Graz,	Austria
3  The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, U.S.A.
4 The University of Queensland Diamantina Institute, Translational 
Research Institute, Woolloongabba, 4102 Queensland, Australia
Acquired cancer drug resistance (ACDR) is a major challenge 
for effective cancer therapies including targeted therapies.  
ACDR has so far been explained as a process of clonal 
selection of few cells which gradually acquire random 
favorable mutations or epigenetic changes during drug 
exposure.  
However our studies deliver evidence for induction of 
stemness as a primary survival mechanism, of cancer cells 
when exposed to persistent challenging environmental 
conditions such as hypoxia, glucose starvation and drug 
exposure.  The transition is characterized by a gain of multi-
drug tolerant state along with expression of the mesenchymal 
stem cell marker CD271 (p75NTR) and ALDH activity leading 
to highly angiogenic and tumorigenic cells.  The cells exhibit 
activation of multiple RTKs resulting in persistent AKT-
MAPK signaling activation enabling the cells to undergo 
continuous signaling maneuver against targeted inhibitors. 
Hence we propose a model of combining a primary drug with 
distinct secondary drugs targeting the transition from parent 
state to stem like state which includes CD271 inhibitors, 
HDAC inhibitors, and PI3-AKT inhibitors. Employing these 
combinations together with drug holidays may prevent or 
delay acquired drug resistance.  
A COMPARISON OF IMAGING MODALITIES TO DETERMINE 
RIGHT VENTRICULAR PACING LEAD POSITION 
Peter Moore, Cardiology Registrar
Princess Alexandra Hospital 
Background:  Traditionally the right ventricular apex (RVA) 
has been the site of choice for pacemaker lead placement, 
but this may be deleterious to cardiac haemodynamics.  
Studies aimed at comparing outcomes of pacing at different 
right ventricular sites have been hampered by an inability 
to determine final lead position.  The aim of this study is to 
determine the most effective imaging modality to determine 
the position of a pacing lead within the right ventricle.
Methods:  All patients undergoing routine clinically relevant 
implantation of an MRI safe pacemaker at the Princess 
Alexandra Hospital will be considered for this study.  Thirty 
patients will be recruited: 15 with RVA pacing and 15 with 
non-apical pacing.  All patients will undergo cardiac MRI, 
CTCA, echocardiography and ECG in order to define pacing 
lead position.  Standard descriptive statistics will be used to 
compare the efficacy of each modality.
Conclusion: This study will identify the most effective modality 
in identifying pacemaker lead position within the right ventricle. 
This will assist in future studies aimed at comparing long-term 
outcomes of right ventricular pacing at different sites. 
OVERCOMING A NUTRITION EVIDENCE-PRACTICE GAP IN 
NEONATAL CRITICAL CARE USING TRANSLATIONAL RESEARCH 
METHODOLOGY.    
Denise Page1,2,3, Melissa Gilroy1,2,3, Elizabeth Hurrion4, 
Shelley Wilkinson3,5
1  Advanced Dietitian, Neonatal and Paediatric Dietitian, Mater Mothers’ 
Hospital, Mater Health Services, Brisbane, Queensland, Australia, 4101
2  MRI-UQ TRIP Interns (2014)
3  Mothers & Babies Theme,  MRI-UQ 
4 Neonatology Staff Specialist in Neonatology, Mater Mothers’ Hospital, 
Mater Health Services, Brisbane, Queensland, Australia, 4101
5  Senior	Maternity	Health	Research	Fellow,	Department	of	Nutrition	&	
Dietetics, Mater Health Services, Brisbane, Queensland, Australia, 4101
Preterm infants (born <37 weeks gestation and <1500g) need 
optimal nutrition to support growth and brain development to 
prevent profound cognitive disabilities.  Tsang’s Reasonable 
Nutrient Intakes (RNIs) 2005 indicate that infants born <1500g 
should receive 2g protein/kg/day and 40-50kCal/kg/day in 
the first 24 hours of life, with quick initiation and ongoing 
adequate nutrition showing evidence of both short and long 
term benefits. An earlier study in Mater’s Neonatal Critical 
Care Unit demonstrated that approximately 50% of staff 
believe infants receive sufficient nutrition and in a timely 
manner.  However, audits show almost no infant receives 
their nutrition needs in the first 24 hours of life and <50% 
receive sufficient protein at 2 weeks of age.  To determine and 
subsequently design an intervention to overcome the barriers 
to evidence–based practice we are systematically exploring 
the beliefs and perceptions of Neonatologists, Neonatal 
Fellows and Nursing Staff through semi-structured interviews 
using theory-based framework. We will present emerging 
themes (barriers) and highlight methodological approaches 
we will implement over our 1 year TRIP internship in the 
Neonatal Critical Care Unit.
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GROUP THERAPY IN BRAIN INJURY REHABILITATION; A STUDY 
OF PROCESSES AND EFFECTIVENESS.
Ms Freyr Patterson, Associate Professor Jennifer Fleming,  
Dr Emmah Doig
Princess Alexandra Hospital
Traumatic brain injury (TBI) is a major cause of long-
term disability, disrupting participation in life roles and 
occupations, and resulting in significant economic and social 
costs.  Literature identifies several advantages to the use of 
group therapy interventions in rehabilitation including: cost 
effectiveness; opportunities to learn and practice skills/
strategies to achieve competence in daily life activities; and 
opportunities for peer support. 
At the Brain Injury Rehabilitation Unit, PAH, Brisbane there 
is an existing group therapy program which addresses 
participation in activities and roles, upper limb and 
cognitive-behavioural impairments. Limited research 
evidence exists to guide the delivery of group interventions 
in TBI rehabilitation.  The research aims to enhance the 
group therapy program as well as translate findings into 
development of clinical guidelines that will be more widely 
applicable for TBI rehabilitation.  This will be achieved by 
analysis of videotaped group therapy sessions, clinician focus 
groups and, interviews and questionnaires of patients with 
TBI (consumers) and families involved in the occupational 
therapy group program.  This research will inform and 
enhance rehabilitation practice and service development of 
group-based therapy interventions for people with TBI.
TARGETING MACROPHAGES USING CSF-1 IS A VIABLE 
APPROACH TO ENHANCE FRACTURE HEALING 
Pettit AR1, Wullschleger ME2, Wu AC1, Alexander KA1, Kaur S1, 
Maugham M3, Steck R3, Gregory L3, Raggatt LJ1 
1 Mater Research-UQ, Translational Research Institute, Australia  
2 Caboolture Hospital and The University of Queensland, Australia
3 Institute of Health and Biomedical Innovation, Queensland University of 
Technology, Australia 
Bone fracture is a significant and increasing burden on 
health resources.  Resident macrophages (osteomacs) 
within bone facilitate pro-anabolic outcomes via supporting 
osteoblast function. We used a pre-clinical internally fixed 
(MouseFix) femoral fracture model to elucidate the breadth of 
macrophage contributions to fracture repair and whether they 
can be targeted to enhance healing. Immunohistochemistry 
demonstrated that macrophages were present throughout all 
phases of fracture healing with inflammatory macrophages 
predominated in early events and osteomacs participating in 
hard callus formation.  
In macrophage depleted mice callus formation was abolished 
or significantly reduced when macrophage depletion was 
initiated at surgery or delayed until after the inflammatory 
phase, respectively.  Local administration of the macrophage 
growth factor CSF-1 significantly increased soft callus 
formation by 2.5 fold.  These data provide definitive 
demonstration of the important contribution of macrophages 
in multiple stages of fracture repair and provide proof-of-
concept that macrophages/osteomacs can be therapeutically 
targeted to enhance fracture healing. 
FORODERM ENHANCED DRUG AND RADIOTHERAPY FOR 
TREATING ACTINIC KERATOSIS
Tarl Prow, Ph.D.
Dermatology Research Centre, School of Medicine, University of 
Queensland 
Treating actinic keratoses, precursors to squamous cell 
carcinoma, is the focus of this project. Current drug therapies 
only mask the lesion temporarily, instead of treating the 
cause of the disease. Cryotherapy effectively destroys 
the lesion but leaves the patient with a permanent scar.  
Therefore there is a need for a more effective, less invasive 
and targeted therapy for treating actinic keratosis lesions.
We have used next generation sequencing to uncover 
potential drug targets.  I have separately developed a novel 
gold coated microparticle technology for enhancing low 
dose radiotherapy, supported by in vitro experiments. In this 
Project we will use targeted therapy to treat these increasingly 
common lesions using my Foroderm technology as the 
platform.
The idea would be to deliver new drugs to inhibit pathways 
activated in skin cancer and to explore the potential for gold 
microparticle enhanced radiotherapy, all using the Foroderm 
platform.
This Project has the potential to generate new intellectual 
property and pilot data for NHMRC and ARC project grants.  
Further, this project will help establish collaborative 
partnerships between my group and the PAH radio-oncology 
team. 
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DETECTING CIRCULATING TUMOUR CELLS IN METASTATIC 
HEAD AND NECK SQUAMOUS CELL CARCINOMA
Arutha Kulasinghe1, Chris Perry2, Lidija Jovanovic3,  
Colleen Nelson3, Chamindie Punyadeera1
1   University of Queensland Diamantina Institute, University of 
Queensland, Translational Research Institute, Woolloongabba, QLD 
4102, Australia
2   Department of Otolaryngology, Princess Alexandra Hospital, 
Woolloongabba, QLD 4102, Australia
3   Australian prostate cancer research centre Queensland/Queensland 
University of Technology, Translational Research Institute, 
Woolloongabba, QLD 4102, Australia
Head and neck squamous cell carcinoma (HNSCC) is the 6th 
most common cancer with less than 40% survival beyond 
5 years. Metastatic disease is responsible for 88% of 
patient deaths within 12 months of diagnosis. The ability to 
identify high risk patients with disseminated disease prior 
to presenting with clinically detectable metastases holds 
remarkable potential. Circulating tumour cells (CTCs) are a 
hallmark of invasive cancer cells expressing epithelial cell 
adhesion molecule (EpCAM) and key to metastasis. CTCs 
have been used as surrogate markers of overall survival and 
progression free survival for breast, prostate and colorectal 
cancers using the CellSearch® system. The aim of this study 
is to use CellSearch® (FDA-approved) and ScreenCell® to 
detect and compare CTCs in HNSCC. In a cohort of 21 HNSCC, 
CTCs were detected in 2 patients.  To increase the number 
of CTCs, we are looking at a broader range of epithelial and 
mesenchymal markers which are not selected for by the 
CellSearch®. Preliminary data displays some degree of 
mesenchymal nature is present, suggesting of an epithelial to 
mesenchymal transition.
SPHINGOSINE KINASE1 IS A NOVEL E2F7-DEPENDENT 
EFFECTOR THAT REGULATES ANTHRACYCLINE SENSITIVITY IN 
SQUAMOUS CELL CARCINOMA (SCC)
Mehlika Hazar Rethinam
Translational Research Institute
SCC is a common and potentially fatal malignancy and there 
is considerable need for selective agents to treat SCC. We 
have characterised novel, important, and non-redundant 
role for E2F7 (one of the recently identified E2Fs) in the 
regulation of sensitivity to cytotoxic stimuli.  We showed 
that E2F7-deficient keratinocytes are selectively sensitive 
to the cytotoxic actions of doxorubicin and not to other 
chemotherapeutic agents. A series of microarray studies 
were undertaken in order to identify the downstream effector 
of E2F7 axis in SCC cells.  We showed that E2F7-mediated 
sensitivity to doxorubicin is regulated by Sphingosine kinase 
1 (Sphk1).  
Importantly, a number of Sphk1 inhibitors have been 
described and tested in preclinical setting. Significantly, 
silencing Sphk1 by shRNA or blocking Sphk1 activity by a 
specific Sphk1 inhibitor, SK1-I (BML258), in combination with 
low doses of doxorubicin sensitises cells to chemotherapy-
induced cytotoxicity in vitro and tumour regression in vivo.  
These findings define a previously undescribed pathway that 
contributes to anthracycline resistance in SCC, and identifies 
a novel combination of Sphk1 inhibitor and anthracycline as a 
potentially curative option for treating advanced SCC.
SYNBIOTICS EASING RENAL FAILURE BY IMPROVING GUT 
MICROBIOLOGY (SYNERGY): A RANDOMISED-CONTROLLED 
TRIAL
Megan Rossi
Princess Alexandra Hospital
Modifying gut microbiota and subsequent bacterial 
fermentation through the administration of synbiotics (pre- 
and probiotics) to patients with chronic kidney disease (CKD) 
represents a promising, novel, cheap and safe strategy for 
inhibiting gut production of the key uremic nephrovascular 
toxins, indoxyl sulphate (IS) and p-cresyl sulphate (PCS), 
thereby potentially mitigating the risks of CKD progression 
and cardiovascular disease (CVD).  To date, translation of this 
novel therapy into clinical practice has been impeded by a 
lack of quality trials. 
In this randomised cross-over trial, participants with stage 
4/5 CKD will be randomised to synbiotic therapy or placebo 
for 6 weeks, with a 4 week washout period between cross-
over. The primary outcome is serum IS and PCS. Secondary 
outcomes include serum endotoxin levels, inflammatory and 
oxidative stress biomarkers, albuminuria, quality of life and 
adverse events. 
This trial will provide high-level, quality evidence for the 
safety and efficacy of synbiotics as a promising nutritional 
therapy targeting uremic toxins that contribute to the very 
high risk of kidney failure progression and CVD in CKD 
patients.
44
Meeting of Minds
Forum 2014
THE FATTY ACID SYNTHASE INHIBITOR TRICLOSAN: 
EVALUATION OF AN OLD BACTERICIDE FOR A NEW PURPOSE 
IN PROSTATE CANCER
Martin C. Sadowski1, Rebecca H. Pouwer2, Jennifer H. Gunter1, 
Amy A. Lubik1,3, Ronald J. Quinn2 and Colleen C. Nelson1,3,*
1 Australian Prostate Cancer Research Centre - Queensland, Institute 
of Health and Biomedical Innovation, Queensland University of 
Technology, Princess Alexandra Hospital, Translational Research 
Institute, Brisbane, Australia
2	 Eskitis	Institute	for	Drug	Discovery,	Griffith	University,	Brisbane,	
Australia
3 Vancouver Prostate Centre, Department of Urologic Sciences, University 
of British Columbia, Vancouver, Canada
Inhibition of the metabolic oncogene fatty acid synthase 
(FASN) has emerged as a promising target for the treatment 
of cancer.  However, clinical development of current FASN 
inhibitors is challenged by severe adverse effects and 
pharmacological limitations.  The relatively unknown 
synthetic FASN inhibitor triclosan, which was initially 
developed as a topical antibacterial agent, is merely affected 
by these challenges.  Here, we tested triclosan for the first 
time in a panel of eight malignant and non-malignant prostate 
cell lines and compared the cellular and molecular effects 
of triclosan to the well-known synthetic FASN inhibitors 
C75 and orlistat.  Real-time growth analysis revealed that 
triclosan displayed a superior cytotoxic profile and induced 
apoptosis with a several-fold lower IC50. We discovered that 
antagonizing different partial catalytic activities of FASN 
with triclosan, C75 and orlistat disturbed cell morphology, 
cell cycle, lipid content, FASN expression and AMPK status 
differently, suggesting that cytotoxicity was caused by distinct 
mechanisms. Preliminary structure-function relationship 
analysis of triclosan analogs highlighted a hydroxyl group 
as critical for cytotoxic potency.  Together, triclosan is a 
promising FASN inhibitor alternative for drug development 
against prostate cancer.
SALIVARY MIRNAS AS POTENTIAL DIAGNOSTIC BIOMARKERS 
FOR HEAD AND NECK CANCERS
Carolina Salazar
University of Queensland
Aim: Our aims were to: develop a robust method to isolate 
miRNAs from small volumes of saliva and develop a salivary 
diagnostic biomarker panel to detect head and neck 
squamous cell carcinoma (HNSCC). 
Methods: Five differentially expressed miRNAs were selected 
from miScript™ PCR array using saliva from HNSCC patients 
and controls. These were confirmed using RT-qPCR with saliva 
from HNSCC patients and controls (n=56). 
Three-miRNAs were differentially regulated between controls 
and patients (miRNAs 9, 34 and 191). These miRNAS were 
independently validated using HNSCC miRNAseq data from 
The Cancer genome Atlas.  
Results: We isolated on average 600 ng of miRNA from 200 µL 
of saliva. MiRNAs 191 and 9 (fold change= 8.2, 2.8 P< 0.0001 
respectively) were upregulated in the saliva. miR-134 was 
down regulated. miR-9, miR-191 and miR-134 provided a good 
discriminative ability with AUC values of 0.85 (P<0.001), 0.74 
(P< 0.0001) and 0.98 (P= 0.004) respectively. 
Conclusions: We have developed a reliable method to isolate 
miRNAs from small volumes of saliva samples. Salivary miR-
9, miR-191 and miR-134 are potential biomarkers to detect 
HNSCC. 
EARLY CHILDHOOD RESPIRATORY INTERVENTION PREVENTING 
DISEASE PROGRESSION AND HEALTH CARE COST REDUCTION
Associate Professor Andreas Schibler
Staff Specialist – Paediatric Intensive Care Unit, Mater Children’s Hospital
Acute respiratory disease is the leading cause for children 
needing hospital admission.  The main focus of hospital 
treatment is oxygen therapy besides disease specific 
treatment like inhalers for asthma or antibiotics for 
pneumonia. 10-20% of these children need a higher level of 
care, and will be transferred to a children’s hospital intensive 
care unit.  This is expensive and imposes a huge burden 
on health care and is very stressful for these children and 
families. Over the last eight years we have adapted a new 
respiratory system; the high flow nasal cannula (HFNC) to 
the need of children, and have shown the advantageous 
physiological effect and demonstrated in our institution 
that the use of HFNC reduces the need for intensive care 
admission.  In alignment with WHO global Plan of Action we 
investigate collaboratively in an international randomised 
controlled trial (Kenya and Uganda) the role of HFNC in 
children with respiratory disease, whether early intervention 
reduces mortality and health care costs.  This early respiratory 
intervention is a fundamentally new approach, which has 
the potential to prevent progression and deterioration of 
respiratory illness. 
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A NOVEL TREATMENT APPROACH FOR OBESITY- TARGETING 
BRAIN NICOTINIC RECEPTORS WITH CHAMPIX™
Masroor Shariff, Michael Morgan, Paul Klenowski,  
Selena E. Bartlett
Addiction Neuroscience and Obesity Group
Translational Research Institute
Institute of Health and Biomedical Innovation, Queensland University of 
Technology
Obesity is a growing epidemic worldwide.  It is estimated that 
annual costs arising from obesity-related illnesses exceed 
$56.6 billion dollars in Australia alone, with 80% of the 
Australian population predicted to be overweight and obese 
by 2025.  Sugar directly contributes to significant weight gain 
and therefore obesity.  Sugar is as addictive as alcohol and 
nicotine and our lab has recently shown that it directly targets 
brain nicotinic receptors in the nucleus accumbens, a key 
brain region associated with reward.  Furthermore, we also 
show sucrose consumption changes the morphology of these 
neurons. The main goals of our research are to translate these 
findings into novel treatments for patients.   Therefore, we 
have demonstrated that the FDA-approved nicotine cessation 
medication, Champix™, reduces sugar addiction in animals 
by targeting the mesolimbic reward pathway of the brain. As 
the compound is FDA-approved, we are planning small-scale 
proof-of-concept studies in humans.  Taken together, our 
results demonstrate a completely novel treatment strategy for 
weight control associated with sugar addiction but equally 
importantly highlight the brain reward centre as a promising 
consideration in developing treatment approaches for 
obesity.
STOP THE TRAFFIC: A WAY TO CONQUER EPITHELIAL CANCER
Fiona Simpson 
University of Queensland
The majority of squamous cell carcinoma (SCC) over-express 
the Epidermal growth Factor (EgFR). Although EgFR is the 
target of anti-EgFR antibody therapy (Cetuximab), expression 
does not correlate with treatment outcome.  Our novel 
analysis of EgF uptake in patient tumours showed distinct 
differences in EGF trafficking which correlated with patient 
outcome.  Tumour cell death in both Cetuximab-sensitive 
and resistant cell lines could be increased by trapping 
EgFR on the cell surface using endocytosis inhibitors.  
Mechanistic analysis suggests that not only expression level 
but also the way EgFR is presented on the cell membrane 
affects the response of the immune system and its ability 
to destroy tumour cells.  A collaborative proposal between 
UQDI, Princess Alexandra Hospital and the Universities of 
Sydney and Newcastle is underway to enter Phase II clinical 
trials analysing a novel drug combination therapy using 
monoclonal antibodies in combination with commonly used 
anti-psychotic drugs, also known to be potent endocytosis 
inhibitors.  This is an opportunity to improve cancer patient 
outcomes, reverse innate resistance, minimise health costs 
and can be expanded to enhance therapies such as Herceptin 
in breast cancer.
CLOZAPINE: SAFETY IMPLICATIONS OF INCREASED USAGE
This research is a collaboration between Metro South 
Addiction and Mental Health Service, UQ School of Pharmacy, 
UQ School of Medicine and UQ School of Population Health.
Dan Siskind MBBS, MPH, PhD, FRANZCP*1,  
Samantha Hollingworth, PhD2, Karl Winckel, B.Pharm3,  
Tori Forrester BSc4, Andrew Kolomensky BSc5,  
Amanda Wheeler B.Pharm, PhD6
1 Clinical Academic Psychiatrist Queensland Centre for Mental Health 
Research, SPH, UQ & Metro South Addiction and Mental Health 
Services (MSAMHS)
2 UQ School of Pharmacy
3 UQ School of Pharmacy & Princess Alexandra Hospital
4 UQ School of Pharmacy & Princess Alexandra Hospital
5 UQ School of Medicine
6	 Griffith	University,	Griffith	Health	Institute
* presenter - d.siskind@uq.edu.au
Background: Clozapine is the gold standard for treatment-
refractory schizophrenia. Clozapine usage has previously 
been low, partly due to concerns of serious adverse drug 
reactions (ADR), in particular blood dyscrasias and cardiac 
problems. 
Methods: We examined clozapine use within Queensland 
over the last 10 years and analysed reported ADRs. Data 
was extracted from statewide hospital pharmacy dispensing 
records. Correlations between increased use and ADRs were 
investigated and the ramification of increased clozapine use 
in terms of safe and quality use considered.
Results: Clozapine dispensing increased 71% from 2004 
to 2012. Concomitantly there was a 770% increase in the 
number of documented serious ADRs; 7 in 2004 to 61 in 2012. 
This included 23 cardiac ADRs in 2012 compared to only 
one in 2004. Whilst this increased use of clozapine may be 
appropriate, the increase in reported ADRs, including cardiac 
ADRs, is concerning. 
Conclusions: Clozapine usage and reported ADRs has 
increased significantly over the last decade. The potential for 
adverse outcomes should be considered by clinicians and 
service managers alike. Robust monitoring, management and 
reporting systems for ADRs are required.
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NOVEL WOUND HEALING THERAPEUTICS FOR CHRONIC 
WOUNDS FROM NATIVE AUSTRALIAN PLANTS
Annette M. Spierings1, Trudi A. Collet1
1 Indigenous Medicines Group, Tissue Repair and Regeneration Program, 
Cells and Tissue Domain, Institute of Health and Biomedical Innovation, 
Queensland University of Technology
The on-going and in-direct costs of chronic wounds are 
substantial, reaching far beyond the cost of hospitalisation 
and associated care.  Hence, we evaluated the wound healing 
potential of two Australian native plants (denoted A and 
B).  Cellular responses of primary skin cells were measured 
using the alamarBlue® and CyQUANT® assays as per 
manufacturer’s instructions.  Plant extracts in the aqueous 
phase were prepared by boiling whole leaves in water and 
taking samples at 1, 2 and 5 minute time points post-boiling.  
Plant leaves were added either prior to boiling (cold boiled) or 
subsequent to boiling (hot boiled) at final concentrations of 
3.3 ng/mL (± 0.3 ng/mL) per sample.  Antimicrobial properties 
of the plant extracts were tested using the well diffusion 
assay against various species of wound colonising bacteria.  
Both native plants contain bioactive compounds that increase 
cellular metabolic rates and total nucleic acid content 
(p=0.03), thus indicating an increase in cell proliferation.  
Neither plant was shown to be cytotoxic.  Importantly, plant A 
exhibited significant antimicrobial activity against methicillin 
resistant Staphylococcus aureus, Klebsiella pneumoniae and 
Bacillus cereus (p=0.0009).
TIDYING UP TO MEET NEAT: SAFELY IMPROVING NEAT 
COMPLIANCE 
Sullivan CM, Staib A , Flores J, Scanlon A and Scott I
Princess	Alexandra	Hospital,Ipswich	Road	Woolloongabba,	Brisbane
Background: The NEAT target (National Emergency Access 
Targets: the 4 hour rule) is a major KPI for the Diamantina 
Health Partners clinical facilities.  Princess Alexandra Hospital 
(PAH) (Figure 1)  has recently reported the nation’s most 
improved NEAT compliance.  There have been few previous 
studies tracking the inpatient mortality of ED patients during 
the improvement of NEAT compliance.  
Aims: To improve NEAT performance while maintaining 
patient safety
Methods: Multiple interventions were undertaken  to improve 
the NEAT compliance of the hospital. Safety was closely 
monitored by a suite of indicators tracking critical events 
and the mortality of patients admitted via the emergency 
department.  
Findings: PAH NEAT compliance has improved from 
approximately 30% to approximately  70%.   There was no 
change in the hospital standardised mortality rate (HSMR) 
and a decline in the mortality of inpatients admitted from the 
ED (Figure 2 and  3)
Conclusions: NEAT compliance has improved efficiencies 
and has been associated with a decline in the mortality of 
patients admitted from the emergency department. 
GADD45G AS A POTENTIAL THERAPEUTIC TARGET IN 
PROSTATE CANCER TREATMENT
Raja S Vasireddy, Dwan R Cochrane, Amy Anne Lubik,  
Ladan Fazli, Melanie L Lehman, Colleen C Nelson
Australian Prostate Cancer Research Centre - Queensland, and Cells 
and Tissue Domain, Institute of Health & Biomedical Innovation (IHBI), 
Queensland University of Technology, Queensland, Australia
Translational Research Institute, Brisbane, Queensland, Australia.
Prostate Cancer is third most common cancer of men with 
approximately 1 in 6 men developing a life threatening 
disease. Alterations in the structure of tumor cell DNA offer 
a survival advantage.  For instance, fusion of different genes 
(e.g TMPRSS2-ERg fusion) is found in tumor cells derived from 
50 to 70% of the PCa patients. In prostate cancer cells fusion 
genes were shown to play a role in development of treatment 
resistance and promoting tumour metastasis.  DNA repair 
proteins were shown to play a role in mediating gene-fusions 
in prostate cancer.
Analysis of tissues derived from prostate tumours showed 
overexpression of a one of the key DNA repair genes- 
gADD45g (growth Arrest and DNA Damage-inducible-45).  
Drugs targeting DNA repair proteins (e.g Olaparib, a PARP1 
inhibitor) are currently under phase-III clinical trials for breast 
cancer patients but still under investigation in PCa patients. 
We hypothesize that inhibition of gADD45g reduces the 
frequency of the gene fusions and thus the risk of cancer. In 
contrast to conventional therapies gADD45g inhibitors will 
specifically target tumor cells resulting in the less treatment 
related side-effects.
Research and Innovation Ideas
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COMPUTERISED SCREENING OF FUNCTIONAL SEQUELAE IN 
HEAD/NECK CANCER PATIENTS AND THEIR CARERS
Ms Laurelie Wall1,2,Dr Bena Cartmill2,3, Prof Elizabeth Ward1,2, 
Dr Anne Hill1, Dr Elizabeth, Isenring4, Dr Joshua Byrne5 , 
Prof Suzanne Chambers6, Prof Jeff Dunn7, Mrs Jodie Nixon8, 
Ms Jane Whelan9, Prof Michael Poulson10, A/Prof Sandro 
Porceddu11
The University of Queensland
1 School of Health and Rehabilitation Sciences, UQ 
2 Centre for Functioning and Health Research, PAH
3 Speech Pathology Department, PAH 
4 Dietetics Department, PAH
5	 Centre	for	Applied	Economics,	School	of	Medicine,	Griffith	University
6	 Area	of	Strategic	Investment	for	Chronic	Disease	Prevention,	Griffith	
University
7 Cancer Council Queensland 
8 Occupational Therapy Department, PAH
9 Social Work Department, PAH
10 Radiation Oncology Mater Centre
11 Radiation Oncology Department, PAH
Swallowing and nutritional deficits are common during 
(chemo)radiotherapy ([C]RT) treatment for head/neck cancer 
(HNC). HNC patients and their carers can also experience 
significant anxiety and distress. However, staff/service 
constraints restrict intervention for these sequelae, resulting 
in inadequate or inappropriately scheduled support for this 
population. More effective triaging techniques could help 
identify “at-risk” patients/carers early, and monitor function 
over-time to determine the need for face-to-face intervention.  
Routine screening using patient-reported measures may 
assist in prioritising patients/carers requiring face-to-face 
supportive care. Using existing validated tools, the current 
team have developed an electronic swallowing, nutrition, and 
distress screening tool. The current project will evaluate the 
reliability and validity of these tools to detect “at-risk” HNC 
patient/carers using cross-sectional non-inferiority validation 
methods.   
Potential Outcomes: This novel approach may drive service-
delivery change, improve cost/resource efficiencies and 
enhance holistic care. The current model of computerised 
screening is transferable across cancer diagnoses, thus 
potentially providing broader benefit to multidisciplinary 
oncology teams. Interdisciplinary collaborations between 
hospital, university and not-for-profit organisations can yield 
evidence-based, patient-centred outcomes, whilst improving 
synergy in clinical care and strategic linkages with health 
partners. 
COMPUTERISED PREVENTATIVE SWALLOWING THERAPY FOR 
HEAD/NECK CANCER PATIENTS: A NOVEL SERVICE-DELIVERY 
MODEL
Ms Laurelie Wall1,2, Dr Bena Cartmill2,3, Prof Elizabeth Ward1,2, 
Dr Anne Hill1, Dr Elizabeth, Isenring4, Dr Joshua Byrne5,  
A/Prof Sandro Porceddu6
1 School of Health and Rehabilitation Sciences, UQ 
2 Centre for Functioning and Health Research, Queensland Health
3 Speech Pathology Department, PAH 
4 Dietetics Department, PAH
5	 Centre	for	Applied	Economics,	School	of	Medicine,	Griffith	University	
6 Radiation Oncology Department, PAH
Swallowing difficulties occur in up to 90% of head/neck 
cancer (HNC) patients treated with (chemo)radiotherapy ([C]
RT). Research has shown that prophylactic swallowing therapy 
(completed during [C]RT) can significantly improve swallowing 
outcomes for HNC patients. However, such programs are 
resource-intensive, which limits their provision clinically due 
to staff/service constraints – potentially depriving patients of 
best-practice care.  
Alternate service-delivery models which support patient-
directed home therapy may provide a solution. The current 
team have developed a computerised swallowing therapy 
program, “SwallowIT”, which allows patients to interact 
remotely with clinicians to support independent home-
practice. A three-arm RCT will compare (a) SwallowIT with 
(b) clinician-directed therapy (proven, best practice) and 
(c) patient-directed therapy (standard care). Comparative 
analysis of functional outcomes, adherence and cost-
effectiveness will aim to demonstrate that SwallowIT can 
achieve comparable clinical endpoints and an economic 
benefit to health services. 
Potential Outcomes: This novel approach may drive service-
delivery change, improve cost/resource efficiencies, and 
ultimately optimise patient outcomes. The current model 
of technology-assisted home practice is also transferable 
to other forms of rehabilitation, thus potentially informing 
development of future therapy applications across the 
multidisciplinary team. 
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NOVEL AORTIC COUNTERPULSATION DEVICE FOR HEART 
FAILURE TREATMENT 
Peter Walsh
Princess Alexandra Hospital 
Aortic counterpulsation in the form of intra-aortic balloon 
pumps (IABP) has been used clinically for over 30 years for 
treating acute heart failure.  We have developed a passive 
recoil extra aortic balloon counterpulsation device that 
requires no pump or controller which has shown impressive 
results in animal testing (reduced pulse and mean pressures 
by 27% and 10% respectively, improved left coronary artery 
blood flow by 39%).  We propose to engineer a new device 
in preparation for acute clinical (first in man) testing.  We 
believe our cost effective and simplistic device approach 
has excellent potential as a breakthrough technology for 
longer term use for the 70% of heart failure patients with 
hypertension.
Dr Walsh, Ph.D, is a Senior Biomedical Engineer with 
Biomedical Technology Services at PA Hospital, and has 
worked in R&D for over 10 years and has 5 issued and 3 
pending patents. 
Dr Mundie, MBBS, is Director of Cardiothoracic Surgery 
at PA Hospital and A/Prof of Surgery at the University of 
Queensland, and has over 20 years cardiothoracic surgical 
experience including R&D studies on novel ventricular assist 
devices.
A POSSIBLE THERAPEUTIC APPROACH FOR IMPROVING BONE 
HEALING: MIMICKING A FRACTURE HAEMATOMA
Xin Wang1,2,3, Indira Prasadam3, Vaida Glatt3, Ross Crawford3, 
Paul Masci2, and Yin Xiao3*
1	 Department	of	Spine,	Affiliated	Hospital	of	Zunyi	Medical	College,	
Zunyi,	Guizhou	Province,	China	
2 Translational Research Institute, School of Medicine, University of 
Queensland, Brisbane, Australia
3 Institute of Health and Biomedical Innovation, School of Chemistry, 
Physics, Mechanical Engineering, Queensland University of 
Technology, Brisbane, Australia
Severe traumatic injury leading to critical sized bone defects 
often results in delayed union or non-union of the fracture 
site. Several recently published studies have described the 
importance of hematomas; however, a detailed study on the 
properties of haematoma, specifically comparing natural 
bone healing with a delayed or non-union fracture, has not 
previously been undertaken. 
In this study, a comparison of haematomas from natural and 
delayed or non-union defects have been investigated using 
scanning electron microscopy to determine their structural 
differences at various time points. Furthermore, differences in 
the release of growth factors during clot formation and lysis 
have been determined by quantitative PCR and histology at 
different time points. Finally, the formation of mineralized 
bone tissue has been assessed at days 7 and 14 using 
micro-tomography and histology. Preliminary results from 
SEM analysis showed that a tightly-packed fibrin network 
has been found in delayed defects. A potential outcome from 
this research is to develop a scaffold similar to haematomas 
properties found in bone healing samples. This study will 
provide an innovative solution to enhance large bone defects 
healing. (179 words)
PARTICIPATORY ACTION RESEARCH OF KNOWLEDGE 
TRANSLATION IN OCCUPATIONAL THERAPY
Mary Whitehead¹, Elizabeth Caldwell¹, Sally Bennett² & 
Jennifer Fleming¹
Introduction:  Knowledge translation (KT) is a complex 
process involving change in attitudes, systems and 
behaviours. Through the Princess Alexandra Hospital 
Occupational Therapy Department (PAHOT) Research 
and Evidence in Practice Program (REP) staff have made 
substantial efforts to locate, appraise and implement 
research evidence into their clinical practice. Attitudinal, 
knowledge and resource barriers continue to influence 
behaviour change and implementation success. 
Despite its importance, very little research exists about 
organisational initiatives designed to build clinician lead 
knowledge translation activity. 
Objectives: To introduce and evaluate organisational 
initiatives for clinician lead KT within the PAHOT Department 
to facilitate closure of research-practice gaps in core clinical 
practices and ultimately improve patient outcomes.  
Method or Approach:  Participatory Action Research (PAR) 
design proceeding through a number of stages, each 
informing the following stage. Participants include 20-30 
occupational therapists with data collected by on-line survey 
and focus groups at repeated time points over a 1 year period. 
Conclusion: Findings will assist management to implement 
organisational initiatives to support clinician lead KT 
ultimately leading to improved patient outcomes, as well as 
judicious use of health care resources.
Research and Innovation Ideas
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EVALUATION OF THE TRANSLATION OF A GESTATIONAL 
DIABETES NUTRITION MODEL OF CARE INTO PRACTICE.
Wilkinson, SA1,2,3, McCray, S 4, Beckmann, M 3,5,  
McIntyre, HD3,6
1  Senior Research Dietitian, Mater Mothers’ Hospital, Mater Health 
Services, Brisbane, Queensland, Australia, 4101
2		Former	NHMRC	TRIP	Research	Fellow
3  Mater Research, Mothers’ & Babies Theme
4  Director of Nutrition and Dietetics, Mater Health Services, Brisbane, 
Queensland, Australia, 4101
5  Director of Obstetrics and Gynaecology, Mater Mothers’ Hospital, Mater 
Health Services, Brisbane, Queensland, Australia, 4101
6  Director of Obstetric Medicine, Mater Mothers’ Hospital, Mater Health 
Services, Brisbane, Queensland, Australia, 4101
Aim: To evaluate the translation of a dietetic model of care at 
the Mater Mothers Hospital’s antenatal clinic.  
Methods: The planned implementation consisted of 9-month 
pre- and post-phases.  Primary outcomes were uptake of the 
new model and requirement for pharmacotherapy. 
Results: Both phases ran for 7 months; integration took 4 
months.  Pre-intervention, none of the 91 women with gDM 
seen received ≥ 1 dietetic follow-up appointment. Post-
intervention, significantly more women (50.6%) received 
best-practice care (2+reviews) (p = 0.02).  However, due to 
heavy clinical demand, only 31.5 % of the 162 women seen 
after the change in practice received one-on-one dietitian 
review at their first visit, deviating from best-practice.  Trends 
were seen in changes in medication requirements; with the 
percentage of women requiring pharmacologic treatment 
decreasing from 31.1% to 26.9% with institution of the new 
model of care.  This difference was more pronounced in 
women who received best-practice care. 
Conclusions: This project successfully increased the 
proportion of women seen according to best practice, 
however service limitations demonstrated the effect of partial 
adherence to the model of care on medication requirements. 
VASCULAR BONE MARROW NICHES PROTECT ACUTE MYELOID 
LEUKAEMIA STEM CELLS FROM CHEMOTHERAPY
Winkler IG
Mater Research Institute
We recently found the vascular adhesion molecule E-selectin 
is a key component of the bone marrow vascular niche, 
‘awakening’ otherwise dormant haematopoietic stem cells 
(HSCs) (Winkler et al., Nat Med 2012). E-selectin expression 
increases in the bone marrow (~10 to 20-fold) during 
the recovery phase from chemotherapy or radiotherapy, 
awakening HSC that must cycle to replenish the blood. When 
E-selectin is absent (in gene deleted mice) or therapeutically 
blocked (using small molecule antagonists), a greater 
proportion of HSC return to quiescence. 
Vascular niche E-selectin is also up-regulated in mice with 
acute myeloid leukaemia (AML), so we tested the hypothesis 
that E-selectin-mediated signalling can protect LSC from the 
effects chemotherapy. Indeed, we found absence of E-selectin 
has no effect on LSC numbers, but increased their sensitivity 
to chemotherapy. We have recruited an industry partner 
to repeat these studies using a clinical grade E-selectin 
antagonist, with a view to potential phase I/II clinical trials 
within the two years. 
In summary niche factors can strongly influence LSC 
sensitivity to chemotherapy and their blockade may improve 
therapeutic outcome and complement current treatment 
strategies.
THE NON-CANONICAL TOLL-LIKE RECEPTOR RP105 PROMOTES 
INNATE IMMUNE RESPONSES AGAINST MYCOBACTERIAL 
INFECTION 
Chien-Hsiung Yu1, Massimo Micaroni2, Andreas Puyskens1, 
Thomas E. Schultz1, Amanda C. Stanley2, Jennifer L. Stow2  
and Antje Blumenthal1 
1  The University of Queensland Diamantina Institute, Brisbane QLD 4102, 
Australia
2  Institute for Molecular Bioscience, Brisbane QLD 4072, Australia 
Mycobacterial infections, in particular tuberculosis, remain a 
significant public health concern worldwide. Radioprotective 
105 kDa (RP105) is a member of Toll-like receptor (TLR) family 
that recognises a group of pathogen-associated molecular 
patterns (PAMPs) by cells of the innate immune system, 
such as macrophages.  Our group recently demonstrated 
that canonical TLR signalling including activation of MAP 
kinase and NF-βB signalling, typically known to regulate the 
innate immune activation, remained intact in RP105-deficient 
macrophages during mycobacterial infection.  Furthermore, 
mycobacteria-induced mRNA and protein expression of 
cytokines such as TNF and IL-6 were comparable in wild-
type and RP105-deficent macrophages. Sufficient cytokine 
production is associated with tuberculosis susceptibility 
and severity.  In contrast, we showed that RP105-deficient 
macrophages infected with mycobacteria displayed 
significantly reduced cell surface-associated TNF, suggesting 
dysfunctional trafficking machinery for TNF and possibly other 
cytokines in these cells. In conclusion, we identify RP105 a 
novel role as an integral part of the innate immune receptor 
complex for pathogenic mycobacteria.  Unlike other well-
known TLR members, RP105 contributes to optimal innate 
immune responses by regulating trafficking of cytokines 
independent of classical TLR signalling. 
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Turn Your Ideas Into Action!
Use this conference booklet to convert your conference notes into ideas and actions over the 
next two days. 
Float your ideas with other conference participants and leave Forum 2014 with some clear 
ideas about what you want to do and how you are going to go about making those ideas a 
reality.
Try to listen for and record
Ideas
If the light bulb goes on make sure you capture it before you lose it.
Questions
What do you need to think through further or who do you need to talk to?
Quotes
Note down the words that inspire you.
Actions
Start a to do list for after the conference.
Stories
Note down any stories that you have heard or want to remember.
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Ideas I am going to progress Steps needed to turn ideas into action
1.
2.
3.
4.
5.
Turn Your Ideas Into Action!
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Ideas
actionsquotes
questions
stories
Turn Your Ideas Into Action!
Thank You!
Thank you for attending the 2nd Annual Diamantina 
Health Partners Forum. 
We hope you enjoyed the past 2 days. 
DHP’s progress is continuous.  You are encouraged to be 
part of this uplifting productive journey.
The Annual Forum will be a punctuating event and your 
ideas and involvement in planning next year’s event will 
be very welcoming.
Email Areti Gavrilidis, Executive Consultant – 
Diamantina Health Partners 
areti.gavrilidis@diamantina.org.au
3 0  A P R I L  –  2  M A Y  2 0 1 4  •  B R I S B A N E  A U S T R A L I A
Meeting of Minds
translate – transfer – transform
